Novel arylthiadiazole derivatives and salts thereof useful for preventing and treating human viral infection and a novel virucide which contains the arylthiadiazole derivative or a salt thereof are provided. n,N-dimethyl [3-(3-(amino-2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl] carbamate or its salt, and virucide containing the same as an effective component.
|
6. An arylthiadiazole derivative represented by general formula below, or a salt thereof: ##STR245## where R11, R12, and R13 are independently a hydrogen atom, a halogen atom, an alkyl group of 1 to 6 carbons, a trifluoromethyl group, an alkoxyl group of 1-4 carbons, a hydroxyl group, or a nitro group; and
n3 is 0 or 1 provided that R11, R12, and R13 are not simultaneously a hydrogen atom when n3 is 0.
2. An arylthiadiazole derivative represented by general formula below, or a salt thereof: ##STR239## where R9, and R10 are independently a hydrogen atom, or an alkyl group of 1-6 carbons;
R11, R12, and R13 are independently a hydrogen atom, a halogen atom, an alkyl group of 1 to 6 carbons, a trifluoromethyl group, an alkoxyl group of 1-4 carbons, a hydroxyl group, or a nitro group; R14 is a hydrogen atom, an alkyl group of 1-6 carbons, or a phenyl group (which may be substituted by a halogen, an alkyl of 1-6 carbons, or an alkoxyl of 1-4 carbons).
5. An arylthiadiazole derivative represented by general formula below, or a salt thereof: ##STR244## where Y1 is an oxygen atom or a sulfur atom;
n2 is 1 or 2; R11, R12, and R13 are independently a hydrogen atom, a halogen atom, an alkyl group of 1 to 6 carbons, a trifluoromethyl group, an alkoxyl group of 1-4 carbons, a hydroxyl group, or a nitro group; R14 is a hydrogen atom, an alkyl group of 1-6 carbons, or a phenyl group (which may be substituted by a halogen, an alkyl of 1-6 carbons, or an alkoxyl of 1-4 carbons); and R19 is a hydrogen atom, or an alkyl group of 1-6 carbons which may be substituted by an alkoxyl of 1-4 carbons.
4. An arylthiadiazole derivative represented by general formula below, or a salt thereof: ##STR243## where Y1 is an oxygen atom or a sulfur atom;
W is an oxygen atom or a sulfur atom; R11, R12, and R13 are independently a hydrogen atom, a halogen atom, an alkyl group of 1 to 6 carbons, a trifluoromethyl group, an alkoxyl group of 1-4 carbons, a hydroxyl group, or a nitro group; R14 is a hydrogen atom, an alkyl group of 1-6 carbons, or a phenyl group which may be substituted by a halogen, an alkyl of 1-6 carbons, or an alkoxyl of 1-4 carbons; and R18 is an alkyl group of 1-6 carbons which is substituted by a hydroxyl, a cyano, a carboxyl, a carbamoyl, or a carbonyl substituted by an alkoxyl of 1-4 carbons.
9. A virucidal composition, comprising a pharmaceutically acceptable carrier and a virucidally effective amount of an arylthiadiazole derivative of general formula or a or a salt thereof: ##STR248## where R11, R12, and R13 are independently a hydrogen atom, a halogen atom, an alkyl group of 1 to 6 carbons, a trifluoromethyl group, an alkoxyl group of 1-4 carbons, a hydroxyl group, or a nitro group;
A is ##STR249## where Y1 is an oxygen atom or a sulfur atom; n2 is 1 or 2; R17 is a halogen atom, or Y2 --R19 ; Y2 is an oxygen atom, a sulfur atom, or --NR14 --; R14 is a hydrogen atom, an alkyl group of 1-6 carbons, or a phenyl group (which may be substituted by a halogen, an alkyl of 1-6 carbons, or an alkoxyl of 1-4 carbons); and R19 is a hydrogen atom, or an alkyl group which may be substituted by an alkoxyl of 1-4 carbons.
3. An arylthiadiazole derivative represented by general formula below, or a salt thereof: ##STR240## where n3 is 0 or 1; W is an oxygen atom or a sulfur atom;
R4, and R5 are independently a hydrogen atom, an alkoxyl group of 1-4 carbons, an alkyl group of 1-6 carbons which may be substituted by an alkoxyl of 1-4 carbons, a hydroxyl, a cyano, a carboxyl, a carbamoyl, a carbonyl substituted by alkoxyl of 1-4 carbons, or a group of ##STR241## or R4 and R5 linked together to form a group of ##STR242## R6, R7, and R8 are independently a hydrogen atom, a halogen atom, an alkyl group of 1-6 carbons, or an alkoxyl group of 1-4 carbons; R9, and R10 are independently a hydrogen atom, or an alkyl group of 1-6 carbons; E is a --CH2 -- group, or an oxygen atom; and n1 is an integer of 0 to 2; and R11, R12, and R13 are independently a hydrogen atom, a halogen atom, an alkyl group of 1 to 6 carbons, a trifluoromethyl group, an alkoxyl group of 1-4 carbons, a hydroxyl group, or a nitro group.
7. A virucidal composition, comprising a pharmaceutically acceptable carrier and an arylthiadiazole of general formula or a salt thereof as an active ingredient: ##STR246## where R11, R12, and R13 are independently a hydrogen atom, a halogen atom, an alkyl group of 1 to 6 carbons, a trifluoromethyl group, an alkoxyl group of 1-4 carbons, a hydroxyl group, or a nitro group;
A is a group of ##STR247## where R14 is a hydrogen atom, an alkyl group of 1-6 carbons, or a phenyl group (which may be substituted by a halogen, an alkyl of 1-6 carbons, or an alkoxyl of 1-4 carbons); R15, and R16 are independently a hydrogen atom, a halogen atom, an alkoxyl group of 1-4 carbons, a nitro group, or an alkyl group of 1-6 carbones which may be substituted with a halogen; R17 is a halogen atom, or Y2 --R19 ; R18 is an alkyl group of 1-6 carbons which is substituted by a hydroxyl, a cyano, a carboxyl, a carbamoyl, or a carbonyl substituted by an alkoxyl of 1-4 carbons; R19 is a hydrogen atom, or an alkyl group which may be substituted by an alkoxyl of 1-4 carbons; J is --CH═, or --N═; n2 is 1 or 2; n3 is 0 or 1; Y2 is an oxygen atom, a sulfur atom, or --NR14 --; R4, R5, R9, R10, R14, Y1, and W are the same as defined above.
1. An arylthiadiazole derivative represented by general formula, or a salt thereof: ##STR236## where Y1 is an oxygen atom or a sulfur atom;
W is an oxygen atom or a sulfur atom; one of R1, R2, and R3 is an amino group which may be substituted by one or two independent alkyls of 1-6 carbons; a carboxyl group; a carbonyl group which is substituted by an alkoxyl of 1-4 carbons; a carbamoyl group which may be substituted by one or two independent alkyls of 1-6 carbons; a cyano group; or an alkyl group of 1-6 carbons which is substituted by a hydroxyl, an alkoxyl of 1-4 carbons, an alkoxyl of 1-4 carbons (which is further substituted by another alkoxyl of 1-4 carbons), or a silyloxy (which is substituted by three independent alkyls of 1-6 carbons); the other two of R1, R2, and R3 are independently a hydrogen atom; a halogen atom; an alkyl group of 1-6 carbons which may be substituted by a hydroxyl, an alkoxyl of 1-4 carbons, an alkoxyl of 1-4 carbons (which is further substituted by another alkoxyl of 1-4 carbons), or a silyloxy (which is substituted by three independent alkyls of 1-6 carbons; a trifluoromethyl group; an alkoxyl group of 1-4 carbons; a carboxyl group; a carbonyl group which is substituted by an alkoxyl of 1-4 carbons; a carbamoyl group which may be substituted by one or two independent alkyls of 1-6 carbons; a cyano group; a hydroxyl group; a hydroxymethyl group; a nitro group; or an amino group which may be substituted by one or two independent alkyls of 1-6 carbons; R4, and R5 are independently a hydrogen atom, an alkoxyl group of 1-4 carbons, an alkyl group of 1-6 carbons which may be substituted by an alkoxyl of 1-4 carbons, a hydroxyl, a cyano, a carboxyl, a carbamoyl, a carbonyl (substituted by alkoxyl of 1-4 carbons), or a group of ##STR237## or R4 and R5 are linked together to form a group of ##STR238## R6, R7, and R8 are independently a hydrogen atom, a halogen atom, an alkyl group of 1-6 carbons, or an alkoxyl group of 1-4 carbons; R9, and R10 are independently a hydrogen atom, or an alkyl group of 1-6 carbons; E is a --CH2 -- group, or an oxygen atom; and n1 is an integer of 0 to 2.
8. A virucidal composition, comprising a pharmaceutically acceptable carrier and a virucidally effective amount of the arylthiadiazole derivative of
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This application is a 371 of PCT/JP95/01898 filed on Sep. 21, 1995
1. Field of the Invention
The present invention relates to arylthiadiazole derivatives and salts thereof having antiviral activity.
2. Description of the Related Art
Thiadiazoles having herbicidal activity are described in JP-A-3-193773, JP-A-4-103575, and JP-A-4-117372. Thiadiazoles useful as an agricultural fungicide are described in JP-A-4-182403, and JP-A-4-182405. On the other hand, acyclovir (antiherpetic medicine), amantadine (antiinfluenzal medicine), azidothymidine (anti-HIV medicine, HIV: human immunodeficiency virus) are known as antiviral medicines.
No medicine is effective against viral diseases at the moment, so that effective antiviral medicines are desired to be developed. In particular, development of anti-HIV medicine is urgent.
After comprehensive investigation, it was found by the inventors of the present invention that arylthiadiazole derivatives have excellent antiviral activity. Based on the findings, the present invention has been accomplished.
The present invention provides arylthiadiazole derivatives represented by General Formula [I], and salts thereof: ##STR1## where Y1 is an oxygen atom or a sulfur atom; W is an oxygen atom or a sulfur atom; one of R1, R2, and R3 is an amino group which may be substituted by one or two independent alkyls of 1-6 carbons; a carboxyl group; a carbonyl group which is substituted by an alkoxyl of 1-4 carbons; a carbamoyl group which may be substituted by one or two independent alkyls of 1-6 carbons; a cyano group; or an alkyl group of 1-6 carbons which is substituted by a hydroxyl, an alkoxyl of 1-4 carbons, an alkoxyl of 1-4 carbons (which is further substituted by another alkoxyl of 1-4 carbons), or a silyloxy group (which is substituted by three independent alkyls of 1-6 carbons); the other two of R1, R2, and R3 are independently a hydrogen atom; a halogen atom; an alkyl group of 1-6 carbons which may be substituted by a hydroxyl, an alkoxyl of 1-4 carbons, an alkoxyl of 1-4 carbons (which is further substituted by another alkoxyl of 1-4 carbons), or a silyloxy (which is substituted by three independent alkyls of 1-6 carbons; a trifluoromethyl group; an alkoxyl group of 1-4 carbons; a carboxyl group; a carbonyl group which is substituted by an alkoxyl of 1-4 carbons; a carbamoyl group which may be substituted by one or two independent alkyls of 1-6 carbons; a cyano group; a hydroxyl group; a hydroxymethyl group; a nitro group; or an amino group which may be substituted by one or two independent alkyls of 1-6 carbons; R4, and R5 are independently a hydrogen atom, an alkoxyl group of 1-4 carbons, an alkyl group of 1-6 carbons which may be substituted by an alkoxyl of 1-4 carbons, a hydroxyl, a cyano, a carboxyl, a carbamoyl, a carbonyl (substituted by alkoxyl of 1-4 carbons), or a group of ##STR2## or R4 and R5 are linked together to form a group of ##STR3## R6, R7, and R8 are independently a hydrogen atom, a halogen atom, an alkyl group of 1-6 carbons, or an alkoxyl group of 1-4 carbons; R9, and R10 are independently a hydrogen atom, or an alkyl group of 1-6 carbons; E is a --CH2 -- or an oxygen atom; and n1 is an integer of 0 to 2.
The present invention also provides a virucide containing the arylthiadiazole derivative represented by General Formula [I] or the salt thereof as an active ingrdient.
The present invention further provides arylthiadiazole derivatives represented by the formulas below, and salts thereof: ##STR4## where n2 is 1 or 2; n3 is 0 or 1;
Y1 is an oxygen atom or a sulfur atom;
W is an oxygen atom or a sulfur atom;
R11, R12, and R13 are independently a hydrogen atom, a halogen atom, an alkyl group of 1 to 6 carbons, a trifluoromethyl group, an alkoxyl group of 1-4 carbons, a hydroxyl group, or a nitro group;
R14 is a hydrogen atom, an alkyl group of 1-6 carbons, or a phenyl group (which may be substituted by a halogen, an alkyl of 1-6 carbons, or an alkoxyl of 1-4 carbons);
R18 is an alkyl group of 1-6 carbons which is substituted by a hydroxyl, a cyano, a carboxyl, a carbamoyl, or a carbonyl substituted by an alkoxyl group of 1-4 carbons;
R19 is a hydrogen atom, or an alkyl group of 1-6 carbons which may be substituted by an alkoxyl of 1-4 carbons;
R4, R5, R6, R7, R8, R9, R10, E, and n1 are the same as mentioned above, provided that, in the last formula, R11, R12, and R13 are not simultaneously a hydrogen atom when n3 is 0.
The present invention further provides a virucide containing an arylthiadiazole of General Formula [II], or a salt thereof as an active ingredient: ##STR5## where A is a group of ##STR6## where R15, and R16 are independently a hydrogen atom, a halogen atom, an alkoxyl group of 1-4 carbons, a nitro group, or an alkyl group of 1-6 carbons which may be substituted with a halogen;
J is --CH═, or --N═;
Y2 is an oxygen atom, a sulfur atom, or --NR14 --;
R17 is a halogen atom, or NR14 --R19 ; and
R11, R12, R13, R14, R18, R19, n2, n3, R4, R5, R9, R10, R14, Y1, and W are the same as mentioned above.
The present invention is described in more detail.
The alkyl group of 1-6 carbons as the substituent in General Formulas [I] and [II] includes linear, branched, or cyclic alkyl groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, t-butyl, n-pentyl, cyclopentyl, n-hexyl, and cyclohexyl. The alkoxyl group of 1-4 carbons includes methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, s-butoxy, and t-butoxy. The halogen atoms includes atoms of fluorine, chlorine, bromine, and iodine.
Typical production processes are shown for the arylthiadiazole derivative represented by General Formula [I] or [II].
Production Process 1 ##STR7## where Q is a chlorine, bromine, or iodine atom; R1, R2, R3, R4, R5, Y1, and W are the same as mentioned above.
The arylthiadiazole derivative represented by General Formula [I] can be produced by reaction of a derivative represented by General Formula [III] with a carbamoyl derivative represented by General Formula [IV].
The reaction is conducted in a solvent in the presence of a base at a temperature of from 0 to 150°C, preferably from 20 to 100° C., for several minutes to 24 hours, preferably from 1 to 12 hours.
The carbamoyl derivative of General Formula [IV] is used in an amount of 1-5 equivalents, preferably 1-3 equivalents, and the base is used in an amount of 1-5 equivalents, preferably 1-3 equivalents, to one equivalent of the derivative of General Formula [III].
The solvent includes hydrocarbons such as hexane, cyclohexane, benzene, toluene, and xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, and dimethoxyethane; halogenated hydrocarbons such as dichloromethane, chloroform, and carbon tetrachloride; amines such as pyridine, and triethylamine; polar solvents such as N,N-dimethylformamide, dimethylsulfoxide, 1,3-dimethyl-2-imidazolidinone, hexamethylphosphoric triamide, and acetonitrile; alcohols such as methanol, ethanol, isopropanol, and t-butanol; water, and the like.
The base includes organic bases such as pyridine, triethylamine, and N,N-diisopropylethylamine; inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, and sodium hydride; and alkali metal alkoxides such as sodium methoxide, sodium ethoxide, potassium t-butoxide, and the like.
(Production Process 1-1)
The arylthiadiazole derivative of General Formula [I] in which at least one of R1, R2, and R3 is an alkyl group of 1-6 carbons substituted by a hydroxyl group, and R4, R5, Y1, and W are the same as defined above can be produced by hydrolysis of the arylthiadiazole of General Formula [I] in which at least one of R1, R2, and R3 is an alkyl group of 1-6 carbons [which is substituted by an alkoxyl of 1-4 carbons, an alkoxyl of 1-4 carbons (which is further substituted by another alkoxyl of 1-4 carbons), or a silyloxy (which is further substituted by three independent alkyls of 1-6 carbons)], and R4, R5, Y1, and W are the same as mentioned above.
The reaction is conducted in a solvent in the presence of an acid or a base at a temperature of from 0 to 120°C, preferably from 20 to 100°C, for several minutes to 12 hours, preferably from 1 to 6 hours.
The acid or the base is used in an amount of 1-50 equivalents, preferably 1-20 equivalents to one equivalent of the substrate substance.
The solvent includes hydrocarbons such as hexane, cyclohexane, benzene, toluene, and xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, and dimethoxyethane; halogenated hydrocarbons such as dichloromethane, chloroform, and carbon tetrachloride; polar solvents such as N,N-dimethylformamide, dimethylsulfoxide, 1,3-dimethyl-2-imidazolidinone, hexamethylphosphoric triamide, and acetonitrile; alcohols such as methanol, ethanol, isopropanol, t-butanol; water, and the like.
The base includes inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, and potassium carbonate; and alkali metal alkoxides such as sodium methoxide, sodium ethoxide, potassium t-butoxide, and the like.
The acid includes protonic acids such as acetic acid, trifluoroacetic acid, hydrofluoric acid, hydrochloric acid, hydrobromic acid, and sulfuric acid; and Lewis acids such as aluminum chloride, titanium tetrachloride, boron trifluoride, boron tribromide, zinc bromide, trimethylsilyl iodide, and tetrabutylammonium fluoride.
(Production Process 1-2)
The arylthiadiazole derivative of General Formula [I] in which at least one of R1, R2, and R3 is a carboxyl group, and R4, R5, Y1, and W are the same as defined above can be produced by hydrolysis of the arylthiadiazole of General Formula [I] in which at least one of R1, R2, and R3 is a carbonyl group substituted by an alkoxyl of 1-4 carbons, and R4, R5, Y1, and W are the same as mentioned above.
The reaction is conducted in a solvent in the presence of an acid or a base at a temperature of from 0 to 120°C, preferably from 20 to 100°C, for several minutes to 12 hours, preferably from 1 to 6 hours.
The acid or the base is used in an amount of 1 to 50 equivalents, preferably 1 to 20 equivalents to one equivalent of the substrate substance.
The solvent includes ethers such as diethyl ether, tetrahydrofuran, dioxane, and dimethoxyethane; polar solvents such as N,N-dimethylformamide, dimethylsulfoxide, 1,3-dimethyl-2-imidazolidinone, hexamethylphosphoric triamide, and acetonitrile; alcohols such as methanol, ethanol, isopropanol, and t-butanol; water, and the like.
The base includes inorganic bases such as lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, and potassium carbonate; and alkali metal alkoxides such as sodium methoxide, sodium ethoxide, potassium t-butoxide, and the like.
The acid includes acetic acid, trifluoroacetic acid, hydrofluoric acid, hydrochloric acid, hydrobromic acid, sulfuric acid, trimethylsilyl chloride, boron tribromide, aluminum chloride, and the like.
(Production Process 1-3)
The arylthiadiazole derivative of General Formula [I] in which at least one of R1, R2, and R3 is an amino group which may be substituted by one or two independent alkyls of 1-6 carbons, and R4, R5, Y1, and W are the same as defined above can be produced by reduction, with hydrogen, of the arylthiadiazole derivative of General Formula [I] in which at least one of R1, R2, and R3 is a nitro group, and R4, R5, Y1, and W are the same as mentioned above in the presence of a catalyst such as platinum oxide, platinum, platinum-carbon, platinum sulfide-carbon, and palladium-carbon. Further, the amino group can be alkylated by reaction of the resulting amino group with an alkylating agent of 1-6 carbons, if necessary.
The reduction reaction is conducted in a solvent in the presence or absence of an acid at a temperature of from 0 to 80°C, preferably from 10 to 50°C, for several minutes to 24 hours, preferably from 1 to 12 hours.
The catalyst is used in an amount of 0.01 to 1 part, preferably 0.03 to 0.3 part by weight, and the acid is used in an amount of 0.1 to 10 parts, preferably 0.5 to 3 parts by weight to one part by weight of the substrate substance. The hydrogen pressure is 1 to 5 atmosphere, preferably 1 to 2 atmosphere.
The solvent includes hydrocarbons such as hexane, cyclohexane, benzene, toluene, and xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, and dimethoxyethane; halogenated hydrocarbons such as dichloromethane, chloroform, and carbon tetrachloride; polar solvents such as N,N-dimethylformamide, dimethylsulfoxide, 1,3-dimethyl-2-imidazolidinone, hexamethylphosphoric triamide, acetonitrile and ethyl acetate; alcohols such as methanol, ethanol, isopropanol, and t-butanol; acetic acid; water, and the like.
The catalyst includes platinum oxide, platinum, platinum-carbon, platinum sulfide-carbon, palladium-carbon, and the like.
The acid includes acetic acid, hydrochloric acid, sulfuric acid, phosphoric acid, oxalic acid, trifluoroacetic acid, and the like.
The alkylation of the resulting amino group is conducted by reaction with an alkylating agent of 1-6 carbons in a solvent in the presence or absence of a base at 0 to 130°C, preferably 20 to 100°C, for several minutes to 24 hours, preferably 1 to 12 hours.
The alkylating agent of 1-6 carbons is used in an amount of 0.5 to 5 equivalents, preferably 1 to 3 equivalents, to one equivalent of the substrate substance.
The alkylating agent includes alkyl halides, alkyl sulfate esters, and the like.
The solvent includes hydrocarbons such as hexane, cyclohexane, benzene, toluene, and xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, and dimethoxyethane; halogenated hydrocarbons such as dichloromethane, chloroform, and carbon tetrachloride; polar solvents such as N,N-dimethylformamide, dimethylsulfoxide, 1,3-dimethyl-2-imidazolidinone, hexamethylphosphoric triamide, acetonitrile and ethyl acetate; alcohols such as methanol, ethanol, isopropanol, and t-butanol; amines such as pyridine, triethylamine, and N,N-diisopropylethylamine; water, and the like.
The base includes organic bases such as pyridine, triethylamine, N,N-diisopropylethylamine; inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, and sodium hydride; and alkali metal alkoxides such as sodium methoxide, sodium ethoxide, potassium t-butoxide, and the like.
Production Process 2 ##STR8## where R1, R2, R3, R4, R5, Y1, and W are the same as mentioned above.
The arylthiadiazole derivative represented by General Formula [I] can be produced by reaction of a derivative represented by General Formula [III] with a carbonylating agent, and subsequent reaction with an amine represented by General Formula [V].
The carbonylation is conducted in a solvent in the presence or absence of a base at 0 to 100°C, preferably 10 to 50°C, for several minutes to 24 hours, preferably 1 to 12 hours.
The carbonylating agent is used in an amount of 1 to 3 equivalents, preferably 1 to 2 equivalents, and the base is used in an amount of 1 to 5 equivalents, preferably 1 to 3 equivalents to one equivalent of the derivative represented by General Formula [III].
The carbonylating agent includes phosgene, thiophosgene, trichloromethyl chloroformate, bis(trichloromethyl) carbonate, 1,1'-thiocarbonyldiimidazole, 1,1'-carbonyldiimidazole, dimethyl carbonate, and the like.
The solvent includes hydrocarbons such as hexane, cyclohexane, benzene, toluene, and xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, and dimethoxyethane; and halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and the like.
The base includes organic bases such as pyridine, triethylamine, N,N-diisopropylethylamine; inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, and sodium hydride; and alkali metal alkoxides such as sodium methoxide, sodium ethoxide, potassium t-butoxide, and the like.
The subsequent reaction with the amine represented by General Formula [V] is conducted in a solvent in the presence or absence of a base at 0 to 100°C, preferably 10 to 50°C, for several minutes to 24 hours, preferably 1 to 12 hours.
The amine of General Formula [V] is used in an amount of 1 to 5 equivalents, preferably 1 to 3 equivalents, and the base is used in an amount of 1 to 5 equivalents, preferably 1 to 3 equivalents to one equivalent of the derivative represented by General Formula [III].
The solvent includes hydrocarbons such as hexane, cyclohexane, benzene, toluene, and xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, and dimethoxyethane; and halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and the like.
The base includes organic bases such as pyridine, triethylamine, N,N-diisopropylethylamine; inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, and sodium hydride; and alkali metal alkoxides such as sodium methoxide, sodium ethoxide, potassium t-butoxide, and the like.
Production Process 3 ##STR9## where R1, R2, R3, R4, Y1 and W are the same as mentioned above.
The arylthiadiazole represented by General Formula [I-a] can also be produced by reaction of a derivative represented by General Formula [III] with an isocyanate represented by General Formula [VI].
The reaction is conducted in a solvent in the presence or absence of a base at 0 to 150°C, preferably 20 to 100°C, for several minutes to 24 hours, preferably 1 to 12 hours.
The isocyanate represented by General Formula [VI] is used in an amount of 1 to 30 equivalents, preferably 1 to 10 equivalents, and the base is used in an amount of 0.01 to 3 equivalents, preferably 0.01 to 1 equivalent to one equivalent of the derivative represented by General Formula [III].
The solvent includes hydrocarbons such as hexane, cyclohexane, benzene, toluene, and xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, and dimethoxyethane; halogenated hydrocarbons such as dichloromethane, chloroform, and carbon tetrachloride; amines such as pyridine, and triethylamine; and polar solvents such as N,N-dimethylformamide, dimethylsulfoxide, 1,3-dimethyl-2-imidazolidinone, hexamethylphosphoric triamide, acetonitrile, and the like.
The base includes organic bases such as pyridine, triethylamine, and N,N-diisopropylethylamine; inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, and sodium hydride; and alkali metal alkoxides such as sodium methoxide, sodium ethoxide, potassium t-butoxide, and the like.
Production Process 4 ##STR10## where R9, R10, R11, R12, R13, and R14 are the same as mentioned above.
The arylthiadiazole derivative represented by General Formula [II-a] can be produced by reaction of an amide derivative represented by General Formula [VII] with phosphorus oxychloride, and subsequent reaction with an amine derivative represented by General Formula [VIII].
The reaction with phosphorus oxychloride is conducted in a solvent at 0 to 100°C, preferably from 10 to 50°C, for several minutes to 24 hours, preferably 3 to 12 hours.
The phosphorus oxychloride is used in an amount of from 0.3 to 1.5 equivalents, preferably from 0.5 to 1.1 equivalents to one equivalent of the amide derivative represented by General Formula [VII].
The solvent includes hydrocarbons such as hexane, cyclohexane, benzene, toluene, and xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, and dimethoxyethane; and halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and the like.
The subsequent reaction with the amine derivative represented by General Formula [VIII] is conducted in the same solvent used for the reaction with phosphorus oxychloride at 10 to 130°C, preferably 50 to 90°C, for several minutes to 12 hours, preferably 1 to 6 hours.
The amine derivative represented by General Formula [VIII] is used in an amount of 0.25 to 1 equivalent, preferably 0.5 to 1.0 equivalent to 1 equivalent of the amide derivative represented by General Formula [VII].
Production Process 5 ##STR11## where R11, R12, R13, n3, and Q are the same as mentioned above.
The carboxylic acid derivative represented by General Formula [X] can be produced by reaction of a halogen compound represented by General Formula [IX] with a cyanating agent, and subsequent hydrolysis by an acid or a base.
The reaction with the cyanating agent is conducted in a solvent at 10 to 180°C, preferably 50 to 150°C, for several minutes to 24 hours, preferably 1 to 12 hours.
The cyanating agent is used in an amount of 1 to 5 equivalents, preferably 1 to 3 equivalents to one equivalent of the halogen compound represented by General Formula [IX].
The solvent includes ethers such as diethyl ether, tetrahydrofuran, dioxane, and dimethoxyethane; and polar solvents such as N,N-dimethylformamide, dimethylsulfoxide, 1,3-dimethyl-2-imidazolidinone, hexamethylphosphoric triamide, acetonitrile, and the like.
The cyanating agent includes sodium cyanide, potassium cyanide, copper cyanide, and the like.
The subsequent hydrolysis reaction is conducted in a solvent in the presence of an acid or a base at 0 to 120°C, preferably 20 to 100°C, for several minutes to 12 hours, preferably 1 to 6 hours.
The acid or the base is used in an amount of from 1 to 50 equivalents, preferably 1 to 20 equivalents, to one equivalent of the substrate substance.
The solvent includes ethers such as diethyl ether, tetrahydrofuran, dioxane, and dimethoxyethane; polar solvents such as N,N-dimethylformamide, dimethylsulfoxide, 1,3-dimethyl-2-imidazolidinone, hexamethylphosphoric triamide, and acetonitrile; alcohols such as methanol, ethanol, isopropanol, and t-butanol; water, and the like.
The base includes inorganic bases such as lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, and potassium carbonate; and alkali metal alkoxides such as sodium methoxide, sodium ethoxide, potassium t-butoxide, and the like.
The acid includes formic acid, acetic acid, trifluoroacetic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, and the like.
Production Process 6 ##STR12## where R4, R5, R11, R12, R13, and n3 are the same as mentioned above.
The arylthiadiazole derivative represented by General Formula [II-b] can be produced by reaction of a carboxylic acid derivative represented by General Formula [X] with a chlorinating agent to form an acid chloride represented by General Formula [XI], and subsequent reaction with an amine represented by General Formula [V].
The reaction with the chlorinating agent is conducted without a solvent or in a solvent at 0 to 100°C, preferably 10 to 80°C, for several minutes to 12 hours, preferably 1 to 6 hours.
The chlorinating agent is used in an amount of 1 to 30 equivalents, preferably 1 to 10 equivalents to one equivalent of the carboxylic acid derivative represented by General Formula [X].
The solvent includes hydrocarbons such as hexane, cyclohexane, benzene, toluene, and xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, and dimethoxyethane; halogenated hydrocarbons such as dichloromethane, chloroform, and carbon tetrachloride; amines such as pyridine, and triethylamine; and polar solvents such as N,N-dimethylformamide, dimethylsulfoxide, 1,3-dimethyl-2-imidazolidinone, hexamethylphosphoric triamide, and the like.
The chlorinating agent includes thionyl chloride, oxalyl chloride, phosphoryl chloride, phosphorus trichloride, phosphorus pentachloride, and the like.
A brominating agent or an iodinating agent can be used in place of the chlorinating agent for the reaction.
The subsequent reaction with the amine represented by General Formula [V] is conducted in a solvent in the presence or absence of a base at 0 to 50°C, preferably 0 to 20°C, for several minutes to 6 hours, preferably 0.5 to 2 hours.
The amine represented by General Formula [V] is used in an amount of from 1 to 5 equivalents, preferably from 1 to 2 equivalents, and the base is used in an amount of from 1 to 5 equivalents, preferably 1 to 3 equivalents, to one equivalent of the acid chloride represented by General Formula [XI].
The base includes organic bases such as pyridine, triethylamine, and N,N-diisopropylethylamine; inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, and potassium carbonate; and alkali metal alkoxides such as sodium methoxide, sodium ethoxide, potassium t-butoxide, and the like.
The solvent includes hydrocarbons.such as hexane, cyclohexane, benzene, toluene, and xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, and dimethoxyethane; halogenated hydrocarbons such as dichloromethane, chloroform, and carbon tetrachloride; amines such as pyridine, and triethylamine; polar solvents such as N,N-dimethylformamide, dimethylsulfoxide, 1,3-dimethyl-2-imidazolidinone, hexamethylphosphoric triamide, and acetonitrile; water, and the like.
Production Process 7 ##STR13## where R4, R5, R11, R12, R13, and n3 are the same as mentioned above.
The arylthiadiazole derivative represented by General Formula [II-c] can be produced by reaction of an arylthiadiazole derivative represented by General Formula [II-b] with a sulfidizing agent.
The reaction is conducted in a solvent at 20 to 150°C, preferably 50 to 100°C, for several minutes to 6 hours, preferably 0.5 to 2 hours.
The sulfidizing agent is used in an amount of 1 to 5 equivalents, preferably 1 to 2 equivalents to one equivalent of the arylthiadiazole derivative represented by General Formula [II-b].
The solvent includes hydrocarbons such as hexane, cyclohexane, benzene, toluene, and xylene; halogenated hydrocarbons such as dichloromethane, chloroform, and carbon tetrachloride; and amines such as pyridine, triethylamine, and the like.
The sulfidizing agent includes phosphorus pentasulfide, Lawesson's Reagent, and the like.
Production Process 8 ##STR14## where R11, R12, R13, R17, Y1, and n2 are the same as mentioned above.
The arylthiadiazole derivative represented by General Formula [II-d] can be produced by reaction of a derivative represented by General Formula [XII] with a halogen compound represented by General Formula [XIII].
The reaction is conducted in a solvent in the presence of a base at 0 to 150°C, preferably 20 to 100°C, for several minutes to 24 hours, preferably 1 to 12 hours.
The halogen compound represented by General Formula [XIII] is used in an amount of 1 to 5 equivalents, preferably 1 to 3 equivalents, and the base is used in an amount of 1 to 5 equivalents, preferably 1 to 3 equivalents, to one equivalent of the derivative represented by General Formula [XII].
The solvent includes hydrocarbons such as hexane, cyclohexane, benzene, toluene, and xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, and dimethoxyethane; halogenated hydrocarbons such as dichloromethane, chloroform, and carbon tetrachloride; amines such as pyridine, and triethylamine; polar solvents such as N,N-dimethylformamide, dimethylsulfoxide, 1,3-dimethyl-2-imidazolidinone, hexamethylphosphoric triamide, and acetonitrile; alcohols such as methanol, ethanol, isopropanol, and t-butanol; water, and the like.
The base includes organic bases such as pyridine, triethylamine, and N,N-diisopropylethylamine; inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, and sodium hydride; and alkali metal alkoxides such as sodium methoxide, sodium ethoxide, potassium t-butoxide, and the like.
Production Process 9 ##STR15## where R11, R12, R13, R19, Y1, Y2, n2, and Q are the same as mentioned above.
The arylthiadiazole derivative represented by General Formula [II-f] can be produced by reaction of an arylthiadiazole derivative represented by General Formula [II-e] with a compound represented by General Formula [XIV].
The reaction is conducted in a solvent in the presence of a base at 0 to 150C., preferably 20 to 100°C, for several minutes to 24 hours, preferably 1 to 12 hours.
The compound represented by General Formula [XIV] is used in an amount of 1 to 5 equivalents, preferably 1 to 3 equivalents, and the base is used in an amount of 1 to 5 equivalents, preferably 1 to 3 equivalents, to one equivalent of the arylthiadiazole derivative represented by General Formula [II-e].
The solvent includes hydrocarbons such as hexane, cyclohexane, benzene, toluene, and xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, and dimethoxyethane; halogenated hydrocarbons such as dichloromethane, chloroform, and carbon tetrachloride; amines such as pyridine, and triethylamine; polar solvents such as N,N-dimethylformamide, dimethylsulfoxide, 1,3-dimethyl-2-imidazolidinone, hexamethylphosphoric triamide, and acetonitrile; alcohols such as methanol, ethanol, isopropanol, and t-butanol; water, and the like.
The base includes organic bases such as pyridine, triethylamine, and N,N-diisopropylethylamine; inorganic bases such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, and sodium hydride; and alkali metal alkoxides such as sodium methoxide, sodium ethoxide, potassium t-butoxide, and the like.
Production Process 10 ##STR16## where R11, R12, R13, R14, R18, Y1, and W are the same as mentioned above. The arylthiadiazole derivative represented by General Formula [II-g] can be produced in a similar manner as in Production Process 1, 2, or 3.
(Production Process 10-1)
The arylthiadiazole derivative of General Formula [II-g] in which R18 is an alkyl group of 1 to 6 carbons substituted by a carboxyl or carbamoyl group, and R11, R12, R13, R14, Y1, and W are the same as mentioned above can be produced by hydrolysis of the arylthiadiazole derivative represented by General Formula [II-g] in which R18 is an alkyl group of 1 to 6 carbons substituted by a cyano group, and R11, R12, R13, R14, Y1, and W are the same as above.
The reaction is conducted in a solvent in the presence of an acid or a base at 0 to 120°C, preferably 20 to 100°C, for several minutes to 12 hours, preferably 1 to 6 hours.
The acid or the base is used in an amount of 1 to 50 equivalents, preferably 1 to 20 equivalents, to one equivalent of the substrate substance.
The solvent includes ethers such as diethyl ether, tetrahydrofuran, dioxane, and dimethoxyethane; polar solvents such as N,N-dimethylformamide, dimethylsulfoxide, 1,3-dimethyl-2-imidazolidinone, hexamethylphosphoric triamide, and acetonitrile; alcohols such as methanol, ethanol, isopropanol, t-butanol; water, and the like.
The base includes inorganic bases such as lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, and potassium carbonate; and alkali metal alkoxides such as sodium methoxide, sodium ethoxide, potassium t-butoxide, and the like.
The acid includes formic acid, acetic acid, trifluoroacetic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, and the like.
(Production Process 10-2)
The arylthiadiazole derivative of General Formula [II-g] in which R18 is an alkyl group of 1 to 6 carbons which is substituted by a carbonyl group substituted by an alkoxyl group of 1 to 4 carbons, and R11, R12, R13, R14, Y1, and W are the same as mentioned above can be produced by reaction, with an alcohol of 1 to 4 carbons, of the arylthiadiazole derivative represented by General Formula [II-g] in which R18 is an alkyl group of 1 to 6 carbons substituted by a carboxyl group, and R11, R12, R13, R14, Y1 and W are the same as above.
The reaction is conducted in a solvent in the presence of an acid at 0 to 120°C, preferably 20 to 100°C, for several minutes to 12 hours, preferably 1 to 6 hours.
The acid is used in an amount of 1 to 50 equivalents, preferably 1 to 20 equivalents to one equivalent of the substrate substance.
The solvent includes ethers such as diethyl ether, tetrahydrofuran, dioxane, and dimethoxyethane; polar solvents such as N,N-dimethylformamide, dimethylsulfoxide, 1,3-dimethyl-2-imidazolidinone, hexamethylphosphoric triamide, and acetonitrile; alcohols such as methanol, ethanol, isopropanol, t-butanol; water, and the like.
The acid includes formic acid, acetic acid, trifluoroacetic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, and the like.
Specific examples of the arylthiadiazole derivatives represented by General Formula [I] or [II] are shown in Tables 1 to 26. However, the present invention is not limited thereto.
| TABLE 1 |
| ______________________________________ |
| 1 #STR17## |
| Compound |
| No. R1 |
| R2 |
| R3 |
| Y1 |
| W NR4 R5 |
| ______________________________________ |
| 1 H H 2-NH2 |
| --O-- ═O |
| 2 #STR18## |
| 2 H H 2-NH2 |
| --O-- ═O |
| 3 #STR19## |
| 3 H H 2-NH2 |
| --O-- ═O |
| 4 #STR20## |
| 4 H H 2-NH2 |
| --O-- ═O |
| 5 #STR21## |
| 5 H H 2-NH2 |
| --O-- ═O |
| 6 #STR22## |
| 6 H H 2-NH2 |
| --O-- ═O |
| 7 #STR23## |
| 7 H H 2-NH2 |
| --O-- ═O |
| 8 #STR24## |
| 8 H H 2-NH2 |
| --O-- ═O |
| 9 #STR25## |
| 9 H H 2-NH2 |
| --O-- ═O |
| 0 #STR26## |
| 10 H H 2-NH2 |
| --O-- ═O |
| 1 #STR27## |
| ______________________________________ |
| TABLE 2 |
| __________________________________________________________________________ |
| 1 #STR28## |
| Compound No. |
| R1 |
| R2 |
| R3 |
| Y1 |
| W NR4 R5 |
| __________________________________________________________________________ |
| 11 H H 2-NH2 |
| --O-- |
| ═O |
| 2 #STR29## |
| 12 H H 2-NH2 |
| --O-- |
| ═O |
| 3 #STR30## |
| 13 H H 2-NH2 |
| --O-- |
| ═O |
| 4 #STR31## |
| 14 H H 2-NH2 |
| --O-- |
| ═O |
| 5 #STR32## |
| 15 H H 2-NH2 |
| --O-- |
| ═O |
| 6 #STR33## |
| 16 H H 2-NH2 |
| --O-- |
| ═O |
| 7 #STR34## |
| 17 H H 2-NH2 |
| --O-- |
| ═O |
| 8 #STR35## |
| 18 H H 2-NH2 |
| --O-- |
| ═O |
| 9 #STR36## |
| 19 H H 2-NH2 |
| --O-- |
| ═O |
| 0 #STR37## |
| 20 H H 2-NH2 |
| --O-- |
| ═O |
| 1 #STR38## |
| __________________________________________________________________________ |
| TABLE 3 |
| __________________________________________________________________________ |
| 1 #STR39## |
| Compound No. |
| R1 |
| R2 |
| R3 Y1 |
| W NR4 R5 |
| __________________________________________________________________________ |
| 21 H 2-Cl |
| 5-NH2 |
| --O-- |
| ═O |
| 2 #STR40## |
| 22 H 2-Cl |
| 5-NH2 |
| --O-- |
| ═O |
| 4 #STR41## |
| 23 H 2-Cl |
| 5-NH2 |
| --O-- |
| ═O |
| 9 #STR42## |
| 24 H 2-Cl |
| 5-NHMe --O-- |
| ═O |
| 4 #STR43## |
| 25 H 2-Cl |
| 5-NHMe --O-- |
| ═O |
| 9 #STR44## |
| 26 H 2-Cl |
| 5-NMe2 |
| --O-- |
| ═O |
| 4 #STR45## |
| 27 H 2-Cl |
| 5-NMe2 |
| --O-- |
| ═O |
| 9 #STR46## |
| 28 H 2-Cl |
| 5-CH2 OCH2 OMe |
| --O-- |
| ═O |
| 4 #STR47## |
| 29 H 2-Cl |
| 5-CH2 OCH2 OMe |
| --O-- |
| ═O |
| 9 #STR48## |
| 30 H 2-Cl |
| 5-CH2 OSiMe3 |
| --O-- |
| ═O |
| 4 #STR49## |
| __________________________________________________________________________ |
| TABLE 4 |
| __________________________________________________________________________ |
| 1 #STR50## |
| Compound No. |
| R1 |
| R2 |
| R3 |
| Y1 |
| W NR4 R5 |
| __________________________________________________________________________ |
| 31 H 2-Cl |
| 5-CH2 OSiMe2 |
| --O-- |
| ═O |
| 9 #STR51## |
| 32 H 2-Cl |
| 5-CH2 OH |
| --O-- |
| ═O |
| 4 #STR52## |
| 33 H 2-Cl |
| 5-CH2 OH |
| --O-- |
| ═O |
| 9 #STR53## |
| 34 H 2-Cl |
| 5-CN --O-- |
| ═O |
| 4 #STR54## |
| 35 H 2-Cl |
| 5-CN --O-- |
| ═O |
| 9 #STR55## |
| 36 H 2-Cl |
| 5-CO2 H |
| --O-- |
| ═O |
| 4 #STR56## |
| 37 H 2-Cl |
| 5-CO2 H |
| --O-- |
| ═O |
| 9 #STR57## |
| 38 H 2-Cl |
| 5-CO2 Me |
| --O-- |
| ═O |
| 4 #STR58## |
| 39 H 2-Cl |
| 5-CO2 Me |
| --O-- |
| ═O |
| 9 #STR59## |
| 40 H 2-Cl |
| 5-CONH2 |
| --O-- |
| ═O |
| 4 #STR60## |
| __________________________________________________________________________ |
| TABLE 5 |
| __________________________________________________________________________ |
| 1 #STR61## |
| Compound No. |
| R1 |
| R2 |
| R3 |
| Y1 |
| W NR4 R5 |
| __________________________________________________________________________ |
| 41 H 2-Cl |
| 5-CONH2 |
| --O-- |
| ═O |
| 9 #STR62## |
| 42 H 2-Cl |
| 5-CONHMe |
| --O-- |
| ═O |
| 4 #STR63## |
| 43 H 2-Cl |
| 5-CONHMe |
| --O-- |
| ═O |
| 9 #STR64## |
| 44 H 2-Cl |
| 5-CONMe2 |
| --O-- |
| ═O |
| 4 #STR65## |
| 45 H 2-Cl |
| 5-CONMe2 |
| --O-- |
| ═O |
| 9 #STR66## |
| __________________________________________________________________________ |
| TABLE 6 |
| __________________________________________________________________________ |
| 1 #STR67## |
| Compound No. |
| R1 |
| R2 |
| R3 Y1 |
| W NR4 R5 |
| __________________________________________________________________________ |
| 46 H 2-Cl |
| 3-NH2 |
| --O-- |
| ═O |
| 4 #STR68## |
| 47 H 2-Cl |
| 3-NH2 |
| --O-- |
| ═O |
| 9 #STR69## |
| 48 H 2-Cl |
| 3-NHMe --O-- |
| ═O |
| 4 #STR70## |
| 49 H 2-Cl |
| 3-NHMe --O-- |
| ═O |
| 9 #STR71## |
| 50 H 2-Cl |
| 3-NMe2 |
| --O-- |
| ═O |
| 4 #STR72## |
| 51 H 2-Cl |
| 3-NMe2 |
| --O-- |
| ═O |
| 9 #STR73## |
| 52 H 2-Cl |
| 3-CH2 OCH2 OMe |
| --O-- |
| ═O |
| 4 #STR74## |
| 53 H 2-Cl |
| 3-CH2 OCH2 OMe |
| --O-- |
| ═O |
| 9 #STR75## |
| 54 H 2-Cl |
| 3-CH2 OSiMe2 |
| --O-- |
| ═O |
| 4 #STR76## |
| __________________________________________________________________________ |
| TABLE 7 |
| __________________________________________________________________________ |
| 1 #STR77## |
| Compound |
| No. R1 |
| R2 |
| R3 |
| Y1 |
| W NR4 R5 |
| __________________________________________________________________________ |
| 55 H 2-Cl |
| 3-CH2 OSiMe3 |
| --O-- |
| ═O |
| 2 #STR78## |
| 56 H 2-Cl |
| 3-CH2 OH |
| --O-- |
| ═O |
| 3 #STR79## |
| 57 H 2-Cl |
| 3-CH2 OH |
| --O-- |
| ═O |
| 2 #STR80## |
| 58 H 2-Cl |
| 3-CN --O-- |
| ═O |
| 3 #STR81## |
| 59 H 2-Cl |
| 3-CN --O-- |
| ═O |
| 2 #STR82## |
| 60 H 2-Cl |
| 3-CO2 H |
| --O-- |
| ═O |
| 3 #STR83## |
| 61 H 2-Cl |
| 3-CO2 H |
| --O-- |
| ═O |
| 2 #STR84## |
| 62 H 2-Cl |
| 3-CO2 Me |
| --O-- |
| ═O |
| 3 #STR85## |
| 63 H 2-Cl |
| 3-CO2 Me |
| --O-- |
| ═O |
| 2 #STR86## |
| 64 H 2-Cl |
| 3-CONH2 |
| --O-- |
| ═O |
| 3 #STR87## |
| __________________________________________________________________________ |
| TABLE 8 |
| __________________________________________________________________________ |
| 1 #STR88## |
| Compound |
| No. R1 |
| R2 |
| R3 |
| Y1 |
| W NR4 R5 |
| __________________________________________________________________________ |
| 65 H 2-Cl |
| 3-CONH2 |
| --O-- |
| ═O |
| 2 #STR89## |
| 66 H 2-Cl |
| 3-CONHMe |
| --O-- |
| ═O |
| 3 #STR90## |
| 67 H 2-Cl |
| 3-CONHMe |
| --O-- |
| ═O |
| 2 #STR91## |
| 68 H 2-Cl |
| 3-CONMe2 |
| --O-- |
| ═O |
| 3 #STR92## |
| 69 H 2-Cl |
| 3-CONMe2 |
| --O-- |
| ═O |
| 2 #STR93## |
| __________________________________________________________________________ |
| TABLE 9 |
| __________________________________________________________________________ |
| 1 #STR94## |
| Compound |
| No. R1 |
| R2 |
| R3 |
| Y1 |
| W NR4 R5 |
| __________________________________________________________________________ |
| 70 2-Cl |
| 3-NH2 |
| 6-Cl --O-- |
| ═O |
| 4 #STR95## |
| 71 2-Cl |
| 3-NH2 |
| 6-Cl --O-- |
| ═O |
| 3 #STR96## |
| 72 2-Cl |
| 3-NH2 |
| 6-Cl --O-- |
| ═O |
| 2 #STR97## |
| 73 2-Cl |
| 3-NH2 |
| 6-Cl --O-- |
| ═S |
| 3 #STR98## |
| 74 2-Cl |
| 3-NH2 |
| 6-Cl --O-- |
| ═S |
| 2 #STR99## |
| 75 2-Cl |
| 3-NH2 |
| 6-Cl --S-- |
| ═O |
| 3 #STR100## |
| 76 2-Cl |
| 3-NH2 |
| 6-Cl --S-- |
| ═O |
| 2 #STR101## |
| 77 2-Cl |
| 3-NHMe |
| 6-Cl --O-- |
| ═O |
| 3 #STR102## |
| 78 2-Cl |
| 3-NHMe |
| 6-Cl --O-- |
| ═O |
| 2 #STR103## |
| 79 2-Cl |
| 3-NMe2 |
| 6-Cl --O-- |
| ═O |
| 3 #STR104## |
| __________________________________________________________________________ |
| TABLE 10 |
| __________________________________________________________________________ |
| 1 #STR105## |
| Compound No. |
| R1 |
| R2 R3 |
| Y1 |
| W NR4 R5 |
| __________________________________________________________________________ |
| 80 2-Cl |
| 3-NMe2 |
| 6-Cl |
| --O-- |
| ═O |
| 9 #STR106## |
| 81 2-Cl |
| 3-CH2 OCH2 OMe |
| 6-Cl |
| --O-- |
| ═O |
| 4 #STR107## |
| 82 2-Cl |
| 3-CH2 OCH2 OMe |
| 6-Cl |
| --O-- |
| ═O |
| 9 #STR108## |
| 83 2-Cl |
| 3-CH2 OSiMe3 |
| 6-Cl |
| --O-- |
| ═O |
| 4 #STR109## |
| 84 2-Cl |
| 3-CH2 OSiMe3 |
| 6-Cl |
| --O-- |
| ═O |
| 9 #STR110## |
| 85 2-Cl |
| 3-CH2 OH |
| 6-Cl |
| --O-- |
| ═O |
| 4 #STR111## |
| 86 2-Cl |
| 3-CH2 OH |
| 6-Cl |
| --O-- |
| ═O |
| 9 #STR112## |
| 87 2-Cl |
| 3-CN 6-Cl |
| --O-- |
| ═O |
| 4 #STR113## |
| 88 2-Cl |
| 3-CN 6-Cl |
| --O-- |
| ═O |
| 9 #STR114## |
| 89 2-Cl |
| 3-CO2 H |
| 6-Cl |
| --O-- |
| ═O |
| 4 #STR115## |
| __________________________________________________________________________ |
| TABLE 11 |
| __________________________________________________________________________ |
| 1 #STR116## |
| Compound No. |
| R1 |
| R2 |
| R3 |
| Y1 |
| W NR4 R5 |
| __________________________________________________________________________ |
| 90 2-Cl |
| 3-CO2 H |
| 6-Cl |
| --O-- |
| ═O |
| 9 #STR117## |
| 91 2-Cl |
| 3-CO2 Me |
| 6-Cl |
| --O-- |
| ═O |
| 4 #STR118## |
| 92 2-Cl |
| 3-CO2 Me |
| 6-Cl |
| --O-- |
| ═O |
| 9 #STR119## |
| 93 2-Cl |
| 3-CONH2 |
| 6-Cl |
| --O-- |
| ═O |
| 4 #STR120## |
| 94 2-Cl |
| 3-CONH2 |
| 6-Cl |
| --O-- |
| ═O |
| 9 #STR121## |
| 95 2-Cl |
| 3-CONHMe |
| 6-Cl |
| --O-- |
| ═O |
| 4 #STR122## |
| 96 2-Cl |
| 3-CONHMe |
| 6-Cl |
| --O-- |
| ═O |
| 9 #STR123## |
| 97 2-Cl |
| 3-CONMe2 |
| 6-Cl |
| --O-- |
| ═O |
| 4 #STR124## |
| 98 2-Cl |
| 3-CONMe2 |
| 6-Cl |
| --O-- |
| ═O |
| 9 #STR125## |
| __________________________________________________________________________ |
| TABLE 12 |
| __________________________________________________________________________ |
| 1 #STR126## |
| Compound |
| No. R1 |
| R2 R3 |
| Y1 |
| W NR4 R5 |
| __________________________________________________________________________ |
| 99 2-Cl |
| 3-NH2 |
| 6-F |
| --O-- |
| ═O |
| 3 #STR127## |
| 100 2-Cl |
| 3-NH2 |
| 6-F |
| --O-- |
| ═O |
| 2 #STR128## |
| 101 2-Cl |
| 3-NHMe 6-F |
| --O-- |
| ═O |
| 3 #STR129## |
| 102 2-Cl |
| 3-NHMe 6-F |
| --O-- |
| ═O |
| 2 #STR130## |
| 103 2-Cl |
| 3-NMe2 |
| 6-F |
| --O-- |
| ═O |
| 3 #STR131## |
| 104 2-Cl |
| 3-NMe2 |
| 6-F |
| --O-- |
| ═O |
| 2 #STR132## |
| 105 2-Cl |
| 3-CH2 OCH2 OMe |
| 6-F |
| --O-- |
| ═O |
| 3 #STR133## |
| 106 2-Cl |
| 3-CH2 OCH2 OMe |
| 6-F |
| --O-- |
| ═O |
| 2 #STR134## |
| 107 2-Cl |
| 3-CH2 OSiMe3 |
| 6-F |
| --O-- |
| ═O |
| 3 #STR135## |
| 108 2-Cl |
| 3-CH2 OSiMe3 |
| 6-F |
| --O-- |
| ═O |
| 2 #STR136## |
| __________________________________________________________________________ |
| TABLE 13 |
| ______________________________________ |
| 1 #STR137## |
| Com- |
| pound |
| No. R1 |
| R2 R3 |
| Y1 |
| W NR4 R5 |
| ______________________________________ |
| 109 2-Cl 3-CH2 OH |
| 6-F --O-- ═O |
| 7 #STR138## |
| 110 2-Cl 3-CH2 OH |
| 6-F --O-- ═O |
| 8 #STR139## |
| 111 2-Cl 3-CN 6-F --O-- ═O |
| 7 #STR140## |
| 112 2-Cl 3-CN 6-F --O-- ═O |
| 8 #STR141## |
| 113 2-Cl 3-CO2 H |
| 6-F --O-- ═O |
| 7 #STR142## |
| 114 2-Cl 3-CO2 H |
| 6-F --O-- ═O |
| 8 #STR143## |
| 115 2-Cl 3-CO2 Me |
| 6-F --O-- ═O |
| 7 #STR144## |
| 116 2-Cl 3-CO2 Me |
| 6-F --O-- ═O |
| 8 #STR145## |
| 117 2-Cl 3-CONH2 |
| 6-F --O-- ═O |
| 7 #STR146## |
| 118 2-Cl 3-CONH2 |
| 6-F --O-- ═O |
| 8 #STR147## |
| ______________________________________ |
| TABLE 14 |
| ______________________________________ |
| 1 #STR148## |
| Com- |
| pound |
| No. R1 |
| R2 R3 |
| Y1 |
| W NR4 R5 |
| ______________________________________ |
| 119 2-Cl 3-CONHMe 6-F --O-- ═O |
| 7 #STR149## |
| 120 2-Cl 3-CONHMe 6-F --O-- ═O |
| 8 #STR150## |
| 121 2-Cl 3-CONMe2 |
| 6-F --O-- ═O |
| 7 #STR151## |
| 122 2-Cl 3-CONMe2 |
| 6-F --O-- ═O |
| 8 #STR152## |
| ______________________________________ |
| TABLE 15 |
| ______________________________________ |
| 2 #STR153## |
| Compound |
| No. R11 R12 |
| R13 |
| R14 |
| NR9 N10 |
| ______________________________________ |
| 123 H H H H |
| 9 #STR154## |
| 124 H H 2-Cl H |
| 9 #STR155## |
| 125 H H 2-Me H |
| 9 #STR156## |
| 126 H H 2-MeO H |
| 9 #STR157## |
| 127 H 2-Cl 6-Cl H |
| 9 #STR158## |
| 128 H 2-Cl 6-Cl H |
| 0 #STR159## |
| 129 H 2-Cl 6-Cl H |
| 1 #STR160## |
| 130 H 2-Cl 6-Cl H |
| 2 #STR161## |
| 131 H 2-Cl 6-Cl Me |
| 2 #STR162## |
| 132 H 2-Cl 6-Cl Ph |
| 2 #STR163## |
| ______________________________________ |
| TABLE 16 |
| ______________________________________ |
| 3 #STR164## |
| Compound |
| No. R11 |
| R12 |
| R13 |
| Y1 |
| NR9 R10 |
| ______________________________________ |
| 133 H H H --O-- |
| 9 #STR165## |
| 134 H H 2-Cl --O-- |
| 9 #STR166## |
| 135 H H 2-Me --O-- |
| 9 #STR167## |
| 136 H H 2-MeO --O-- |
| 9 #STR168## |
| 137 H H 2-NO2 |
| --O-- |
| 9 #STR169## |
| 138 H 2-Cl 6-Cl --O-- |
| 9 #STR170## |
| 139 H 2-Cl 6-Cl --O-- |
| 0 #STR171## |
| 140 H 2-Cl 6-Cl --O-- |
| 2 #STR172## |
| 141 H 2-Cl 6-Cl --S-- |
| 9 #STR173## |
| 142 H 2-Cl 6-Cl --S-- |
| 7 #STR174## |
| ______________________________________ |
| TABLE 17 |
| ______________________________________ |
| 4 #STR175## |
| Compound No. |
| R11 |
| R12 |
| R13 |
| Y1 |
| 3 #STR176## |
| ______________________________________ |
| 143 H H H --O-- |
| 4 #STR177## |
| 144 H H 2-Cl --O-- |
| 4 #STR178## |
| 145 H 2-Cl 6-Cl --O-- |
| 4 #STR179## |
| 146 H 2-Cl 6-Cl --O-- |
| 5 #STR180## |
| 147 H 2-Cl 6-Cl --O-- |
| 6 #STR181## |
| 148 H 2-Cl 6-Cl --O-- |
| 7 #STR182## |
| 149 H 2-Cl 6-Cl --O-- |
| 8 #STR183## |
| 150 H 2-Cl 6-Cl --O-- |
| 9 #STR184## |
| 151 H 2-Cl 6-Cl --S-- |
| 4 #STR185## |
| 152 H 2-Cl 6-Cl --S-- |
| 8 #STR186## |
| ______________________________________ |
| TABLE 18 |
| ______________________________________ |
| 5 #STR187## |
| Compound |
| No. R11 |
| R12 |
| R13 |
| Y1 |
| n2 |
| R17 |
| ______________________________________ |
| 153 H H H --O-- 1 --SMe |
| 154 H H 2-Cl --O-- 1 --SMe |
| 155 H 2-Cl 6-Cl --O-- 1 --SMe |
| 156 H 2-Cl 6-Cl --O-- 1 --OMe |
| 157 H 2-Cl 6-Cl --O-- 1 --OCH2 CH2 OMe |
| 158 H 2-Cl 6-Cl --O-- 2 --SMe |
| 159 H 2-Cl 6-Cl --O-- 2 --OMe |
| 160 H 2-Cl 6-Cl --O-- 2 --Br |
| 161 H 2-Cl 6-Cl --O-- 2 |
| 7 #STR188## |
| 162 H 2-Cl 6-Cl --S-- 1 --OCH2 CH2 OMe |
| ______________________________________ |
| TABLE 19 |
| ______________________________________ |
| 6 #STR189## |
| Compound |
| No. R11 R12 R13 |
| n3 |
| ______________________________________ |
| 163 H H 2-Cl 0 |
| 164 H H 3-Cl 0 |
| 165 H H 4-Cl 0 |
| 166 H H 2-Me 0 |
| 167 H H 3-Me 0 |
| 168 H H 4-Me 0 |
| 169 H H 2-F 0 |
| 170 H H 3-F 0 |
| 171 H H 4-F 0 |
| 172 H H 2-CF3 |
| 0 |
| ______________________________________ |
| TABLE 20 |
| ______________________________________ |
| 1 #STR190## |
| Compound |
| No. R11 R12 R13 |
| n3 |
| ______________________________________ |
| 173 H H 3-CF3 |
| 0 |
| 174 H H 4-CF3 |
| 0 |
| 175 H H 2-NO2 |
| 0 |
| 176 H H 3-NO2 |
| 0 |
| 177 H H 4-NO2 |
| 0 |
| 178 H H 2-MeO 0 |
| 179 H H 3-MeO 0 |
| 180 H H 4-MeO 0 |
| 181 H H 2-OH 0 |
| 182 H H 3-OH 0 |
| ______________________________________ |
| TABLE 21 |
| ______________________________________ |
| 1 #STR191## |
| Compound |
| No. R11 R12 R13 |
| n3 |
| ______________________________________ |
| 183 H H 4-OH 0 |
| 184 H 2-Cl 6-Cl 0 |
| 185 H H 2-Cl 1 |
| 186 H H 2-Me 1 |
| 187 H H 2-F 1 |
| 188 H H 2-CF3 |
| 1 |
| 189 H H 2-NO2 |
| 1 |
| 190 H H 2-MeO 1 |
| 191 H H 2-OH 1 |
| 192 H 2-Cl 6-Cl 1 |
| ______________________________________ |
| TABLE 22 |
| __________________________________________________________________________ |
| 2 #STR192## |
| Com- |
| pound |
| No. R11 |
| R12 |
| R13 |
| n3 |
| W NR4 R5 |
| __________________________________________________________________________ |
| 193 H H H 0 ═O |
| 4 #STR193## |
| 194 H H H 0 ═O |
| 5 #STR194## |
| 195 H H 2-Cl |
| 0 ═O |
| 6 #STR195## |
| 196 H H 2-Cl |
| 0 ═S |
| 6 #STR196## |
| 197 H H 2-Cl |
| 0 ═O |
| 7 #STR197## |
| 198 H H 2-Cl |
| 0 ═O |
| 8 #STR198## |
| 199 H 2-Cl |
| 6-Cl |
| 0 ═O |
| 6 #STR199## |
| 200 H 2-Cl |
| 6-Cl |
| 0 ═O |
| 7 #STR200## |
| 201 H H H 1 ═O |
| 4 #STR201## |
| 202 H H 2-Cl |
| 1 ═O |
| 6 #STR202## |
| __________________________________________________________________________ |
| TABLE 23 |
| ______________________________________ |
| 2 #STR203## |
| Compound |
| No. R11 |
| R12 |
| R13 |
| n3 |
| W NR4 R5 |
| ______________________________________ |
| 203 H H 2-Cl 1 ═S |
| 6 #STR204## |
| 204 H H 2-Cl 1 ═O |
| 7 #STR205## |
| 205 H 2-Cl 6-Cl 1 ═O |
| 6 #STR206## |
| 206 H 2-Cl 6-Cl 1 ═O |
| 7 #STR207## |
| ______________________________________ |
| TABLE 24 |
| ______________________________________ |
| 3 #STR208## |
| Com- |
| pound |
| No. R11 |
| R12 |
| R13 |
| Y1 |
| W NR14 R18 |
| ______________________________________ |
| 207 H H H --O-- ═O |
| 7 #STR209## |
| 208 H H 2-Cl --O-- ═O |
| 7 #STR210## |
| 209 H H 3-Cl --O-- ═O |
| 7 #STR211## |
| 210 H H 2-Me --O-- ═O |
| 7 #STR212## |
| 211 H H 3-CF3 |
| --O-- ═O |
| 7 #STR213## |
| 212 H H 2-OMe --O-- ═O |
| 7 #STR214## |
| 213 H H 2-OH --O-- ═O |
| 7 #STR215## |
| 214 H H 2-NO2 |
| --O-- ═O |
| 7 #STR216## |
| 215 H 2-Cl 6-F --O-- ═O |
| 7 #STR217## |
| 216 H 2-Cl 5-NO2 |
| --O-- ═O |
| 7 #STR218## |
| ______________________________________ |
| TABLE 25 |
| __________________________________________________________________________ |
| 3 #STR219## |
| Compound |
| No. R11 |
| R12 |
| R13 |
| Y1 |
| W NR14 R18 |
| __________________________________________________________________________ |
| 217 H 2-Cl |
| 5-OH |
| --O-- |
| ═O |
| 7 #STR220## |
| 218 H 2-Cl |
| 6-Cl |
| --O-- |
| ═O |
| 9 #STR221## |
| 219 H 2-Cl |
| 6-Cl |
| --O-- |
| ═O |
| 7 #STR222## |
| 220 H 2-Cl |
| 6-Cl |
| --O-- |
| ═O |
| 0 #STR223## |
| 221 H 2-Cl |
| 6-Cl |
| --O-- |
| ═O |
| 1 #STR224## |
| 222 H 2-Cl |
| 6-Cl |
| --O-- |
| ═O |
| 2 #STR225## |
| 223 H 2-Cl |
| 6-Cl |
| --O-- |
| ═O |
| 3 #STR226## |
| 224 H 2-Cl |
| 6-Cl |
| --O-- |
| ═O |
| 4 #STR227## |
| 225 H 2-Cl |
| 6-Cl |
| --O-- |
| ═S |
| 7 #STR228## |
| 226 H 2-Cl |
| 6-Cl |
| --S-- |
| ═O |
| 7 #STR229## |
| __________________________________________________________________________ |
| TABLE 26 |
| __________________________________________________________________________ |
| 3 #STR230## |
| Com- |
| pound |
| No. R11 |
| R12 |
| R13 |
| Y1 |
| W NR14 R18 |
| __________________________________________________________________________ |
| 227 H 2-Cl |
| 6-Cl --S-- |
| ═S |
| 7 #STR231## |
| 228 2-Cl |
| 3-Cl |
| 6-Cl --O-- |
| ═O |
| 7 #STR232## |
| 229 2-Cl |
| 3-OH |
| 6-Cl --O-- |
| ═O |
| 7 #STR233## |
| 230 2-Cl |
| 3-NO2 |
| 6-Cl --O-- |
| ═O |
| 7 #STR234## |
| 231 2-Cl |
| 3-NO2 |
| 6-F --O-- |
| ═O |
| 7 #STR235## |
| __________________________________________________________________________ |
The arylthiadiazole derivatives represented by. General Formulas [I] and [II], and salts thereof have useful pharmaceutical properties, in particular, antiviral effects. The medical composition containing the above compound is useful for curative treatment of virus-infected patients, or preliminary treatment of persons who may possibly be infected with a virus.
The DNA type viruses which will be killed by the virucide of the present invention include Herpes simplex virus type 1, Herpes simplex virus type 2, Human cytomegalovirus, Epstein-Barr virus, Varicella zoster virus, and Human herpes virus 6 of Herpesviridae family; Human adenovirus of Adenoviridae family; Hepatitis B virus of Hepadnaviridae family; Human papilloma virus of Papovaviridae family, and the like.
The RNA type viruses which will be killed by the virucide of the present invention include Rubella virus, Japanese encephalitis virus, and Hepatitis C virus of Togaviridae family; Measles virus, Respiratory syncytial virus, and Humps virus of Paramyxoviridae family; Influenza virus of Orthomyxoviridae family; Rabies virus of Rhabdoviridae family; Human T-lymphotropic virus, and Human immunodeficiency virus of Retroviridae family; Human polio virus, and Hepatitis A virus of Picornaviridae family; and the like. In particular, the virucide of the present invention is effective against Human immunodeficiency virus (HIV).
The arylthiadiazole derivative represented by General Formula [I] or [II], or the salt thereof as the virucide can be dosed by oral administration, parenteral administration (hypodermic, intravenous, intramuscular, and sternum injection), or intrarectal administration. For the administration, the arylthiadiazole derivative represented by General Formula [I] or [II], or the salt thereof is dosed in a state of a formulation prepared by mixing with a suitable carrier. The formulation includes tablets, granules, fine grains, powders, capsules, injection, ophthalmic solutions, ophthalmic ointments, and suppositories. The active ingredient is contained in the formulation at a content of from about 0.01 to 99.99%. The dosage depends on the kind of the objective virus, the symptom, the patient's age, and the dosing method, and is usually in the range of from about 0.01 to 500 mg/kg/day in terms of the active ingredient.
The present invention is described specifically by reference to examples without limiting the invention thereto.
Production of N,N-dimethyl [3-(3-amino-2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl] carbamate (Compound 70)
In 10 mL of ethanol, was dissolved 100 mg of N,N-dimethyl [3-(2,6-dichloro-3-nitrophenyl)-1,2,5-thiadiazol-4-yl] carbamate. To this solution, 10 mg of platinum oxide, and 0.1 mL of acetic acid were added, and the mixture was stirred in a hydrogen atmosphere at room temperature. After stirring for 2 hours, the liquid reaction mixture was filtered through Celite. The filtrate is concentrated, and purified by preparative silica gel thin layer chromatography to obtain 80 mg of N,N-dimethyl [3-(3-amino-2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl] carbamate.
Melting Point: 120-123°C
1 H-NMR (Solvent: CDCl3, Unit: δ ppm): 2.90 (s, 3H), 2.95 (s, 3H), 4.3 (br s, 2H), 6.80 (d, J=9 Hz, 1H), 7.16 (d, J=9 Hz, 1H) IR (KBr, cm-1): 3480, 3460, 3390, 3350, 1740, 1620, 1460, 1370, 1325, 1220, 1150, 815
Typical compounds were prepared in the same manner as in Example 1. The properties are shown in Examples 2-5.
N,N-Dimethyl [3-(5-amino-2-chlorophenyl)-1,2,5-thiadiazol-4-yl] CARBAMATE (Compound 21)
Melting Point: 121-124°C
1 H-NMR (Solvent: CDCl3, Unit: δ ppm) 2.93 (s, 3H), 3.03 (s, 3H), 3.4 (br s, 2H), 6.70 (dd, J=3, 8.5 Hz, 1H), 6.76 (d, J=3 Hz, 1H), 7.22 (d, J=8.5 Hz, 1H) IR (KBr, cm-1) 3440, 3340, 1730, 1595, 1455, 1375, 1160, 810
N-Methyl-N-propyl [3-(3-amino-2-chloro-6-fluorophenyl)-1,2,5-thiadiazole-4-yl] carbamate (Compound 99)
Oily matter
1 H-NMR (Solvent: CDCl3, Unit: δ ppm): [0.80 (t, J=7.5 Hz), 0.81 (t, J=7.5 Hz), 3H], [1.48 (sextet, J=7.5 Hz), 1.50 (sextet, J=7.5 Hz), 2H], [2.91 (s), 2.95 (s), 3H], [3.20 (t, J=7.5 Hz), 3.25 (t, J=7.5 Hz), 2H], 3.9 (br s, 2H), 6.7-7.1 (m, 2H) IR (neat, cm-1): 3470, 3360, 1735, 1475, 1385, 1210, 1150
N-Methyl-N-propyl [3-(3-amino-2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl] carbamate (Compound 71)
Oily matter
1 H-NMR (Solvent: CDCl3, Unit: δ ppm): [0.75 (t, J=7.5 Hz), 0.76 (t, J=7.5 Hz), 3H], [1.44 (sextet, J=7.5 Hz), 1.45 (sextet, J=7.5 Hz), 2H], [2.89 (s), 2.90 (s), 3H], [3.16 (t, J=7.5 Hz), 3.21 (t, J=7.5 Hz), 2H], 4.26 (br s, 2H), [6.78 (d, J=9 Hz), 6.79 (d, J=9 Hz), 1H], 7.14 (d, J=9 Hz, 1H) IR (neat, cm-1): 3480, 3360, 1740, 1620, 1460, 1380, 1220, 1150
N-Methyl-N-propyl [3-(5-amino-2-chlorophenyl)-1,2,5-thiadiazol-4-yl] carbamate (Compound 22)
Oily matter
1 H-NMR (Solvent: CDCl3, Unit: δ ppm): [0.81 (t, J=7.5 Hz), 0.83 (t, J=7.5 Hz), 3H], [1.50 (sextet, J=7.5 Hz), 1.53 (sextet, J=7.5 Hz), 2H], [2.91 (s), 2.99 (s), 3H], [3.20 (t, J=7.5 Hz), 3.29 (t, J=7.5 Hz), 2H], 3.70 (br s, 2H), [6.68 (dd, J=3, 8.5 Hz), 6.74 (d, J=3 Hz), 6.75 (d, J=3 Hz), 1H], 7.20(d, J=8.5 Hz, 1H) IR (neat, cm-1): 3460, 3360, 1735, 1460, 1390, 1305, 1210, 1150
Production of N1 -diethyl-N2 - [3-(2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl]formamidine (Compound 130)
0.2 Gram of N,N-diethylformamide was dissolved in 1 mL of benzene. Thereto 0.15 g of phosphorus oxychloride was added. The mixture was stirred at room temperature for 12 hours. To this reaction mixture, 0.12 g of 3-(2,6-dichlorophenyl)-4-amino-1,2,5-thiadiazole was added, and the mixture was refluxed by heating for one hour. Then the mixture was left standing to allow it to cool to room temperature. The reaction mixture was poured into water, and was extracted with ether. The ether layer was washed by 10% sodium hydrodgencarbonate twice, and by water twice, dried over anhydrous magnesium sulfate, and was concentrated. The concentrate was purified by silica gel column chromatography to obtain 0.15 g of N1 -diethyl-N2 -[3-(2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl]formamidine.
Oily matter
1 H-NMR (Solvent: CDCl3, Unit: δ ppm): 1.00 (t, J=7 Hz, 3H,), 1.17 (t, J=7 Hz, 3H), [3.28 (q, J=7 Hz), 3.30 (q, J=7 Hz), 4H], 7.2-7.4 (m, 3H), 8.32 (s, 1H) IR (neat, cm-1): 1610, 1485, 1460, 1425, 1395, 1360, 1125, 795
Typical compounds were prepared in the same manner as in Example 6. The properties are shown in Examples 7-10.
N1 -Dimethyl-N2 -[3-(2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl] formamidine (Compound 127)
Melting Point: 100-103°C
-1 H-NMR (Solvent: CDCl3, Unit: δ ppm): 2.88 (s, 3H), 3.04 (s, 3H), 7.2-7.4 (m, 3H), 8,35 (s, 1H) IR (KBr, cm-1): 1630, 1505, 1470, 1430, 1390, 1120, 1105, 795
N1 -methyl-N1 -propyl-N2 -[3-(2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl]formamidine (Compound 128)
Oily matter
1 H-NMR (Solvent: CDCl3, Unit: δ ppm): 0.73 (t, J=7 Hz, 1H,), 0.88 (t, J=7 Hz, 2H), 1.4-1.7 (m, 2H), 2.86 (s, 2H), 3.02 (s, 1H), 3.25 (q, J=7 Hz, 2H), 7.2-7.4 (m, 3H), 8.35 (s, 1H) IR (neat, cm-1): 1615, 1490, 1465, 1430, 1390, 1125, 795
N1 -diethyl-N2 -[3-(2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl]acetamidine (Compound 131)
Melting point: 39-40°C
1 H-NMR (Solvent: CDCl3, Unit: δ ppm) 0.85 (br s, 3H), 1.11 (br s, 3H), 2.20 (s, 3H), 3.29 (q, J=7 Hz, 4H), 7.2-7.4 (m, 3H) IR (KBr, cm-1): 1560, 1550, 1425, 1390, 1355, 790
N1 -diethyl-N2 -[3-(2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl]benzamidine (Compound 132)
Melting point: 54-55°C
1 H-NMR (Solvent: CDCl3, Unit: δ ppm): 0.99 (t, J=7 Hz, 6H), 3.03 (br, q, J=7 Hz, 2H), 3.49 (br q, J=7 Hz, 2H), 7.1-7.5 (m, 8H) IR (KBr, cm-1): 1565, 1555, 1425, 1390, 1360, 790, 780
Production of 4-(2-chlorophenyl)-1,2,5-thiadiazole-3-carboxylic acid (Compound 163)
In 1,3-dimethyl-2-imidazolidinone, were stirred 280 mg of 3-bromo-4-(2-chlorophenyl)-1,2,5-thiadiazole, and 180 mg of copper cyanide at 150°C for 12 hours. After spontaneous cooling, the reaction mixture was poured into water, and the mixture was extracted with diethyl ether. The diethyl layer was washed with dilute sodium hydroxide solution and water, dried over anhydrous magnesium sulfate, and concentrated. The concentrate was purified by silica gel column chromatography to obtain 120 mg of 3-(2-chlorophenyl)-4-cyano-1,2,5-thiadiazole. The obtained 3-(2-chlorophenyl)-4-cyano-1,2,5-thiadiazole (120 mg) was heated with 6 mL of 5% sodium hydroxide solution and 2 mL of ethanol, and refluxed for one hour. After spontaneous cooling, the reaction mixture was poured into a dilute hydrochloric acid solution, and the mixture was extracted with diethyl ether. The diethyl ether layer was washed with water, dried over anhydrous magnesium sulfate, and concentrated. The concentrate was purified by silica gel column chromatography to obtain 100 mg of 4-(2-chlorophenyl)-1,2,5-thiadiazole-3-carboxylic acid.
Melting point: 112-114°C
IR (KBr, cm-1): 3600-2400, 1705, 1270, 1240, 1165, 750 Elemental analysis (%) as C9 H5 ClN2 O2 S Calculated: C: 44.92, H: 2.09, N: 11.64 Found: C: 44.64, H: 2.19, N: 11.52
Typical compounds were prepared in the same manner as in Example 11. The properties are shown in Examples 12-22.
4-(3-Chlorophenyl)-1,2,5-thiadiazole-3-carboxylic acid (Compound 164)
Melting point: 163-165°C
IR (KBr, cm-1): 3200-2400, 1700, 1460, 1270, 1160, 770 Elemental analysis (%) as C9 H5 ClN2 O2 S Calculated: C: 44.92, H: 2.09, N: 11.64 Found: C: 44.94, H: 2.38, N: 11.84
4-(4-Chlororhenyl) -1,2,5-thiadiazole -3-carboxylic acid (Comound 165)
Melting point: 157-158°C
IR (KBr, cm-1): 3300-2400, 1700, 1465, 1440, 1295, 1160, 1090, 820 Elemental analysis (%) as C9 H5 ClN2 O2 S Calculated: C: 44.92, H: 2.09, N: 11.64 Found: C: 44.68, H: 2.32, N: 11.51
4-(2-Tolyl)-1,2,5-thiadiazole-3-carboxylic acid (Compound 166)
Melting point: 119-121°C
IR (KBr, cm-1) 3300-2400, 1700, 1460, 1450, 1260, 1155, 850, 765, 745 Elemental analysis (%) as C10 H8 N2 O2 S Calculated: C: 54.53, H: 3.66, N: 12.72 Found: C: 54.29, H: 3.89, N: 12.71
4-(3-Tolyl)-1,2,5-thiadiazole-3-carboxylic acid (Compound 167)
Melting point: 118-120°C
IR (KBr, cm-1): 3200-2400, 1700, 1460, 1450, 1280, 1140, 770 Elemental analysis (%) as C10 H8 N2 O2 S Calculated: C: 54.53, H: 3.66, N: 12.72 Found: C: 54.42, H: 3.56, N: 12.71
4-(4-Tolyl)-1,2,5-thiadiazole-3-carboxylic acid (Compound 168)
Melting point: 128-130°C
IR (KBr, cm-1): 3300-2400, 1700, 1455, 1435, 1295, 1150 Elemental analysis (%) as C10 H8 N2 O2 S Calculated: C: 54.53, H: 3.66, N: 12.72 Found: C: 54.33, H: 3.62, N: 12.59
4-(3-Fluorophenyl)-1,2,5-thiadiazole-3-carboxylic acid (Compound 170)
Melting point: 153-156°C
IR (KBr, cm-1): 3200-2400, 1700, 1460, 1210, 870, 855, 770 Elemental analysis (%) as C9 H5 FN2 O2 S Calculated: C: 48.21, H: 2.25, N: 12.49 Found: C: 48.04, H: 2.54, N: 12.69
4-(4-Fluorophenyl)-1,2,5-thiadiazole-3-carboxylic acid (Compound 171)
Melting point: 165-166°C
IR (KBr, cm-1): 3300-2400, 1700, 1460, 1440, 1220, 1160, 830 Elemental analysis (%) as C9 H5 FN2 O2 S Calculated: C: 48.21, H: 2.25, N: 12.49 Found: C: 47.97, H: 2.47, N: 12.48
4-(3-Trifluoromethylphenyl)-1,2,5-thiadiazole-3-carboxylic acid (Compound 173)
Melting point: 122-124°C
IR (KBr, cm-1) 3200-2400, 1700, 1325, 1295, 1155, 1110 Elemental analysis (%) as C10 H5 F3 N2 O2 S Calculated: C: 43.80, H: 1.84, N: 10.22 Found: C: 43.63, H: 2.13, N: 10.41
4-(4-Trifluoromethylphenyl)-1,2,5-thiadiazole-3-carboxylic acid (Compound 174)
Melting point: 135-137°C
IR (KBr, cm-1): 3200-2400, 1700, 1460, 1320, 1160, 1110 Elemental analysis (%) as C10 H5 F3 N2 O2 S Calculated: C: 43.80, H: 1.84, N: 10.22 Found: C: 43.56, H: 2.06, N: 10.20
4-(3-Nitrophenyl)-1,2,5-thiadiazole-3-carboxylic acid (Compound 176)
Melting point: 193-194°C
IR (KBr, cm-1): 3400-2400, 1705, 1525, 1465, 1340 Elemental analysis (%) as C9 H5 N3 O4 S Calculated: C: 43.03, H: 2.01, N: 16.73 Found: C: 42.86, H: 2.29, N: 16.92
4-(4-Methoxyphenyl)-1,2,5-thiadiazole-3-carboxylic acid (Compound 180)
Melting point: 118-120°C
IR (KBr, cm-1): 3200-2400, 1700, 1605, 1460, 1440, 1250, 1155 Elemental analysis (%) as C10 H8 N2 O3 S Calculated: C: 50.84, H: 3.41, N: 11.86 Found: C: 50.60, H: 3.64, N: 11.85
Production of N-methyl-N-propyl 4-(2-chlorophenyl)-1,2,5-thiadiazole-3-carboxamide (Compound 195)
In 1 mL of dichloromethane, was dissolved 50 mg of 4-(2-chlorophenyl)-1,2,5-thiadiazole-3-carboxylic acid. To this solution, 70 mg of thionyl chloride was added. The solution was stirred for one hour. After spontaneous cooling to room temperature, unreacted thionyl chloride was distilled off under a reduced pressure. To the distillation residue, 1 mL of dichloromethane, 73 mg of methylpropylamine were added, and the mixture was stirred at room temperature for 6 hours. Then the reaction mixture was poured into water, and the mixture was extracted with dichloromethane. The dichloromethane layer was washed with two portions respectively of dilute hydrochloric acid, 10% sodium hydrogencarbonate, and water, dried over anhydrous magnesium sulfate, and concentrated. The concentrate was purified by preparative silica gel thin layer chromatography to obtain 50 mg of N-methyl-N-propyl 4-(2-chlorophenyl)-1,2,5-thiadiazole-3-carboxamide.
Oily matter
1 H-NMR (Solvent: CDCl3, Unit: δ ppm) [0.85 (t, J=7.5 Hz), 0.88 (t, J=7.5 Hz), 3H], 1.5-1.8 (m, 2H), [3.02 (s), 3.03 (s), 3H], [3.21 (t, J=7.5 Hz), 3.21 (dd, J=6, 9 Hz), 1H], [3.43 (t, J=7.5 Hz), 3.43 (dd, J=6.9 Hz), 1H], 7.3-7.6 (m, 4H)
Typical compounds were produced in the same manner as in Example 23. The properties are shown in Examples 24-25.
N-Methoxy-N-methyl 4-phenyl-1,2,5-thiadiazole-3-carboxamide (Compound 194)
1 H-NMR (Solvent: CDCl3, Unit: δ ppm):
3.3(s, 3H), 3.5 (s, 3H), 7.2-7.9 (m, 5H) IR (KBr, cm1): 1655, 1480, 1430, 1360, 970, 750
N-(4-Chloro-2-fluorophenyl) 4-(4-chlorophenyl)-1,2,5-thiadiazole-3-carboxamide (Compound 198)
1 H-NMR (Solvent: CDCl3, Unit: δ ppm): 7.0-7.8 (m, 6H), 8.3 (t, J=8 Hz, 1H), 9.1 (br s, 1H) IR (KBr, cm-1): 1690, 1590, 1520, 1480, 1410, 820
Production of [3-(2-chlorophenyl)-1,2,5-thiadiazole-4-yl]acetic acid (Compound 185)
In N,N-dimethylformamide, 290 mg of 3-bromomethyl-4-(2-chlorophenyl)-1,2,5-thiadiazole, and 49 mg of sodium cyanide were stirred at 90°C for 3 hours. After spontaneous cooling, the reaction mixture was poured into water, and was extracted with diethyl ether. The diethyl ether layer was washed with dilute sodium hydroxide solution and water, dried over anhydrous magnesium sulfate, and concentrated. The concentrate was purified by silica gel column chromatography to obtain 150 mg of 3-(2-chlorophenyl)-4-cyanomethyl-1,2,5-thiadiazole. The obtained 150 mg of 3-(2-chlorophenyl)-4-cyanomethyl-1,2,5-thiadiazole, 6 mL of 5% sodium hydroxide solution, and 2 mL of ethanol were mixed and refluxed by heating for one hour. After spontaneous cooling, the reaction mixture was poured into dilute hydrochloric acid, and was extracted with diethyl ether. The diethyl ether layer was washed with water, dried over anhydrous magnesium sulfate, and concentrated. The concentrate was purified by silica gel column chromatography to obtain 120 mg of [3-(2-chlorophenyl)-1,2,5-thiadiazole-4-yl]acetic acid.
1 H-NMR (Solvent: CDCl3, Unit: δ ppm) 3.95 (s, 2H), 7.3-7.6 (m, 3H), 8.4 (br s, 1H)
Production of N-methyl-N-propyl [3-(2-chlorophenyl)-1,2,5-thiadiazol-4-yl]acetamide (Compound 202)
In 1 mL of dichloromethane, was dissolved 30 mg of [3-(2-chlorophenyl)-1,2,5-thiadiazol-4-yl]acetic acid. To this solution, 60 mg of thionyl chloride was added. The mixture was stirred for one hour. After spontaneous cooling to room temperature, unreacted thionyl chloride was distilled off under a reduced pressure. To the distillation residue, 1 mL of dichloromethane, 73 mg of methylpropylamine were added, and the mixture was stirred at room temperature for 6 hours. Then the reaction mixture was poured into water, and was extracted with dichloromethane. The dichloromethane layer was washed with two portions respectively of dilute hydrochloric acid, 10% sodium hydrogencarbonate solution, and water, dried over anhydrous magnesium sulfate, and concentrated. The concentrate was purified by preparative silica gel thin layer chromatography to obtain 20 mg of N-methyl-N-propyl [3-(2-chlorophenyl)-1,2,5-thiadiazol-4-yl]acetamide.
Oily matter,
1 H-NMR (Solvent: CDCl3, Unit: δ ppm): [0.82 (t, J=7.5 Hz), 0.83 (t, J=7.5 Hz), 3H], 1.3-1.6 (m, 2H), [2.86 (s), 2.97 (s), 3H], [3.21 (t, J=7.5 Hz), 3.28 (t, J=7.5 Hz), 2H], 3.92 (s, 2H), 7.3-7.6 (m, 4H)
Producition of N-(3-carboxypropyl)-N-methyl [3-(2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl] carbamate (Compound 222)
In 10 mL of dichloromethane, were dissolved 490 mg of 3-(2,6-dichlorophenyl)-4-hydroxy-1,2,5-thiadiazole, and 210 mg of bis(trichloromethyl) carbonate. Thereto, 170 mg of pyridine was added. The mixture was stirred at room temperature for 12 hours. Thereto, 340 mg of 4-(methylamino)butyric acid hydrochloride, and 570 mg of N,N-diisopropylethylamine were added. The mixture was stirred at room temperature for 12 hours. The reaction mixture was poured into water, and was extracted with dichloromethane. The dichloromethane layer was washed with dilute hydrochloric acid, and water successively, dried over anhydrous magnesium sulfate, and concentrated. The concentrate was purified by silica gel column chromatography to obtain 510 mg of N-(3-carboxypropyl)-N-methyl [3-(2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl] carbamate.
Melting point: 125-126°C
1 H-NMR (Solvent: CDCl3, Unit: δ ppm) 1.6-1.9 (m, 2H), 2.1-2.3 (m, 2H), [2.90 (s), 2.95 (s), 3H], [3.26 (t, J=7.0 Hz), 3.32 (t, J=7.0 Hz), 2H], 7.2-7.5 (m, 3H), 8.5 (br 5, 1H) IR (KBr, cm-1) 3400-2400, 1740, 1700, 1430, 1380, 1295, 1230, 1180, 790
A typical compound was produced in the same manner as in Example 28. The properties of the compound are shown in Example 29.
N-(cyanomethyl)-N-methyl [3-(2,6-dichlorophenvl)-1,2,5-thiadiazol-4-yl] carbamate (Compound 218)
Melting point: 106-107°C
1 H-NMR (Solvent: CDCl3, Unit: δ ppm): [3.02 (s), 3.09 (s), 3H], [4.20 (s), 4.25 (s), 2H], 7.3-7.5 (m, 3H) IR (KBr, cm-1): 2250, 1745, 1430, 1380, 1280, 1230, 1205, 1135, 790, 770
Production of N-(2-cyanoethyl)-N-methyl [3-(2,6-dichlorophenyli-1,2,5-thiadiazol-4-yl] carbamate (Compound 219)
In 50 mL of dichloromethane, were dissolved 1.98 g of 3-(2,6-dichlorophenyl)-4-hydroxy-1,2,5-thiadiazole, and 0.8 g of bis(trichloromethyl) carbonate. Thereto, 0.7 g of pyridine was added. The mixture was stirred at room temperature for 12 hours. Thereto, 1.51 g of N-(2-cyanoethyl)-N-methylamine was added. The mixture was stirred at room temperature for 12 hours. The reaction mixture was poured into water, and was extracted with dichloromethane. The dichloromethane layer was washed with dilute hydrochloric acid, 10% sodium hydrogencarbonate, and water successively, dried over anhydrous magnesium sulfate, and concentrated. The concentrate was purified by silica gel column chromatography to obtain 2.8 g of N-(2-cyanoethyl)-N-methyl [3-(2,6-dichlorophenyl)-1,2,5-thiadiazo1-4-yl] carbamate.
Oily matter
1 H-NMR (Solvent: CDCl3, Unit: δ ppm): [2.46 (t, J=6.5 Hz), 2.51 (t, J=6.5 Hz), 2H], [3.04 (s), 3.12 (s), 3H], [3.49 (t, J=6.5 Hz), 3.59 (t, J=6.5 Hz), 2H], 7.3-7.55 (m, 3H) IR (neat, cm-1): 2250, 1740, 1430, 1380, 1230, 1195, 1125, 790
A typical compound was produced in the same manner as in Example 30. The properties of the compound are shown in Example 31.
N-(2-Hydroxyethyl)-N-methyl [3-(2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl] carbamate (Compound 220)
Melting point: 105-106°C
1 H-NMR (Solvent: CDCl3, Unit: δ ppm): 2.1 (br s, 1H), [2.97 (s), 3.02 (s), 3H], [3.36 (t, J=5.5 Hz), 3.41 (t, J=5.5 Hz), 2H], 3.64 (t, J=5.5 Hz, 2H), 7.3-7.5 (m, 3H) IR (KBr, cm-1): 3550, 1725, 1430, 1380, 1220, 1130, 790
The properties of compounds produced in the same manner as in Example 30 are shown in Examples 32, and 33.
N-Methyl-N-propyl [3-(2,6-dichloro-3-cyanophenyl)-1,2,5-thiadiazol-4-yl] carbamate (Compound 87)
Oily matter
1 H-NMR (Solvent: CDCl3, Unit: δ ppm): [0.76 (t, J=7.4 Hz), 0.80 (t, J=7.4 Hz), 3H], [1.46 (sextet, J=7.4 Hz), 1.50 (sextet, J=7.4 Hz), 2H], [2.89 (s), 2.96 (s), 3H], [3.18 (t, J=7.4 Hz), 3.25 (t, J=7.4 Hz), 2H], 7.55 (d, J=8.5 Hz, 1H), [7.71 (d, J=8.5 Hz), 7.73 (d, J=8.SHz), 1H] IR (neat, cm-1): 2230, 1740, 1395, 1365, 1145
N-Methyl-N-propyl [3-(2,6-dichloro-3-methoxycarbonylphenyl)-1,2,5-thiadiazol-4-yl] carbamate (Compound 91)
Oily matter
1 H-NMR (Solvent: CDCl3, Unit: δ ppm): [0.75 (t, J=7.4 Hz), 0.77 (t, J=7.4 Hz), 3H], [1.40 (t, J=7.4 Hz, 3H), 1.45 (sextet, J=7.4 Hz, 2H), [2.90 (s), 2.93 (s), 3H], [3.18 (t, J=7.4 Hz), 3.22 (t, J=7.4 Hz), 2H], 4.41 (q, J=7.4 Hz, 2H), 7.48 (d, J=8.4 Hz, 1H), [7.83 (d, J=8.4 Hz), 7.85 (d, J=8.4 Hz), 1H] IR (neat, cm-1): 1750, 1745, 1395, 1365, 1300, 1280, 1220, 1180, 1145
Production of N-methyl-N-propyl [3-(3-carbamoyl-2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl] carbamate (Compound 93)
In acetonitrile, a mixture of 80 mg of 3-(3-carbamoyl-2,6-dichlorophenyl)-4-hydroxy-1,2,5-thiadiazole, 41 mg of potassium carbonate, and 41 mg of N-methyl-N-propylcarbamoyl chloride was heated and refluxed for 12 hours. After spontaneous cooling, the reaction mixture was poured into dilute hydrochloric acid, and extracted with ether. The ether layer was washed with water, and saturated aqueous sodium chloride solution successively, dried over anhydrous magnesium sulfate, and concentrated. The concentrate was purified by silica gel column chromatography to obtain 41 mg of N-methyl-N-propyl [3-(3-carbamoyl-2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl] carbamate.
Oily matter
1 H-NMR (Solvent: CDCl3, Unit: δ ppm) 0.78 (t, J=7.3 Hz, 3H), 1.48 (sextet, J=7.3 Hz, 2H), [2.90 (s), 2.94 (s), 3H], [3.18 (t, J=7.3 Hz), 3.23 (t, J=7.3 Hz), 2H], [6.21 (bs), 6.31 (bs), 2H], 7.50 (d, J=8.4 Hz, 1H), [7.78 (d, J=8.4 Hz), 7.80 (d, J=8.4 Hz), 1H] IR (neat, cm-1): 3450, 3330, 3200, 1735, 1670, 1400, 1360, 1225, 1150
The properties of a compound produced in the same manner as in Example 34 are shown in Example 35.
N-Methyl-N-propyl [3-(3-carboxy-2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl] carbamate (Compound 89)
Oily matter
1 H-NMR (Solvent: CDCl3, Unit: δ ppm): [0.66 (t, J=7.6 Hz), 0.71 (t, J=7.6 Hz), 3H], 1.2-1.5 (m, 2H), [2.69 (s), 2.83 (s), 3H], 2.9-3.2 (m, 2H), 7.26 (d, J=8.1 Hz, 1H), 7.5-7.7 (m, 1H) IR (neat, cm-1): 3700-3100., 1740, 1600, 1400, 1390, 1360, 1230, 1150
Production of N-(2-carbamoylethyl)-N-methyl [3-(2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl] carbamate (Compound 223)
In 3 mL of ethanol, was dissolved 360 mg of N-(2-cyanoethyl)-N-methyl [3-(2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl] carbamate. Thereto, 6 mL of concentrated hydrochloric acid was added. The mixture was stirred at 30°C for 2 hours. The reaction mixture was poured into water, and was extracted with diethyl ether. The diethyl ether layer was washed with dilute hydrochloric acid, and water successively, dried over anhydrous magnesium sulfate, and concentrated. The concentrate was purified by silica gel column chromatography to obtain 240 mg of N-(2-carbamoylethyl)-N-methyl [3-(2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl] carbamate.
Melting point: 160-161°C
1 H-NMR (Solvent: CDCl3, Unit: δ ppm) [2.40 (t, J=7.0 Hz), 2.44 (t, J=7.0 Hz), 2H], [2.95 (s), 3.00 (s), 3H], 3.52 (t, J=7.0 Hz), 3.59 (t, J=7.0 Hz), 2H], [5.43 (br s), 5.81 (br s), 2H], 7.3-7.5 (m, 3H) IR (KBr, cm-1): 3440, 3300, 3200, 1735, 1680, 1620, 1455, 1430, 1380, 1305, 1230, 1190, 1130, 790, 780
Production of N-(2-carboxylethyl)-N-methyl [3-(2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl] carbamate (Compound 221)
To 360 mg of N-(2-cyanoethyl)-N-methyl [3-(2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl] carbamate, 10 mL of concentrated hydrochloric acid was added, and the mixture was stirred at 60°C for 6 hours. The reaction mixture was poured into water, and was extracted with diethyl ether. The diethyl ether layer was washed with dilute hydrochloric acid, and water successively, dried over anhydrous magnesium sulfate, and concentrated. The concentrate was purified by silica gel column chromatography to obtain 280 mg of N-(2-carboxyethyl)-N-methyl [3-(2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl] carbamate.
Oily matter
1 H-NMR (Solvent: CDCl3, Unit: δ ppm) [2.52 (t, J=7.0 Hz), 2.53 (t, J=7.0 Hz), 2H], [2.96 (s), 3.01 (s), 3H], [3.49 (t, J=7.0 Hz), 3.58 (t, J=7.0 Hz), 2H], 7.3-7.5 (m, 3H), 9.4 (br s, 1H) IR (neat, cm-1): 3600-2400, 1760-1700, 1430, 1380, 1230, 1190, 1120, 790
Production of N-[2-(ethoxycarbonyl)ethyl]-N-methyl [3-(2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl] carbamate (Compound 224)
In 5 mL of ethanol, was dissolved 200 mg of N-(2-carboxyethyl)-N-methyl [3-(2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl] carbamate. Thereto, 0.2 mL of concentrated hydrochloric acid was added. The mixture was stirred at 60°C for 6 hours. The reaction mixture was poured into water, and was extracted with diethyl ether. The diethyl ether layer was washed with 10% sodium hydrogencarbonate solution, and water successively, dried over anhydrous magnesium sulfate, and concentrated. The concentrate was purified by silica gel column chromatography to obtain 180 mg of N-[2-(ethoxycarbonyl)ethyl]-N-methyl [3-(2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl] carbamate.
Oily matter
1 H-NMR (Solvent: CDCl3, Unit: δ ppm): 1.23 (t, J=7.0 Hz, 3H), [2.43 (t, J=7.0 Hz), 2.44 (t, J=7.0 Hz), 2H], [2.92 (s), 2.98 (s), 3H], [3.47 (t, J=7.0 Hz), 3.56 (t, J=7.0 Hz), 2H], 4.10 (q, J=7.0 Hz, 2H), 7.3-7.5 (m, 3H) IR (neat, cm-1): 1760-1720, 1430, 1380, 1230, 1190, 1120, 790
Production of 3-(2-bromoethoxy)-4-(2,6-dichlorophenyl)-1,2,5-thiadiazole (Compound 160)
In acetonitrile, were mixed and stirred 0.49 g of 3-(2,6-dichlorophenyl)-4-hydroxy-1,2,5-thiadiazole, 0.3 g of potassium carbonate, and 1.9 g of 1,2-dibromoethane at 80°C for one hour. After spontaneous cooling, the reaction mixture was poured into water, and was extracted with diethyl ether. The diethyl ether layer was washed with dilute hydrochloric acid, 10% sodium hydrogencarbonate, and water successively,dried over anhydrous magnesium sulfate, and concentrated. The concentrate was purified by silica gel chromatography to obtain 1.04 g of 3-(2-bromoethoxy)-4-(2,6-dichlorophenyl)-1,2,5-thiadiazole.
Melting point: 60-61°C
1 H-NMR (Solvent: CDCl3, Unit: δ ppm): 3.63 (t, J=6.5 Hz, 2H), 4.77 (t, J=6.5 Hz, 2H), 7.3-7.5 (m, 3H) IR (KBr, cm-1): 1485, 1430, 1410, 1360, 1290, 1245, 790
Production of 3-(2,6-dichlorophenyl)-4-[2-(N-methyl-N-propylamino)ethoxy]-1,2,5-thiadiaz ole (Compound 161)
In dimethoxyethane, were mixed and stirred 0.35 g of 3-(2-bromoethoxy)-4-(2,6-dichlorophenyl)-1,2,5-thiadiazol e, 0.3 g methylpropylamine at 50°C for 6 hours. The reaction mixture was concentrated, and was purified by silica gel chromatography to obtain 0.2 g of 3-(2,6-dichlorophenyl)-4-[2-(N-methyl-N-propylamino)ethoxy]-1,2,5-thiadiaz ole.
Oily matter
1 H-NMR (Solvent: CDCl3, Unit: δ ppm) 0.81 (t, J=7.5 Hz, 3H), 1.41 (sextet, J=7.5 Hz, 3H), 2.25 (s, 3H), 2.32 (t, J=7.5 Hz, 2H), 2.76 (t, J=6.0 Hz, 2H), 4.53 (t, J=6.0 Hz, 2H), 7.2-7.45 (m, 3H) IR (neat, cm-1): 3000-2700, 1520, 1490, 1430, 1245, 1025, 790
Virucidal test aqainst HIV:
In RPMI1640 culture medium containing 20 mM HEPES buffer solution, 10% bovine fetus serum, and 20 μg/mL gentamycin, 3×104 cells of MT-4 (which will be killed by infection with HIV) were infected with HIV at a rate of 0.02 HIV per cell. To the fractions of the culture, predetermined portions of a sample containing the thiadiazole derivative of the compound No. shown in Table 27 and 28 were added, and the culture fractions were incubated at 37°C After incubation for 5 days, living cells were measured by the MTT method to derive the compound concentration (EC50) which is effective to protects 50% of the MT-4 cells from death by HIV. Separately, the MT-4 cells were incubated in the same manner without infection by HIV, and the compound concentration (CC50) which causes death of 50% of the MT-4 cells. The ratio of CC50 /EC50 is the selectivity index (S.I.). The results are shown in Tables 27 and 28.
| TABLE 27 |
| ______________________________________ |
| Compound EC50 CC50 |
| No. (μg/ml) (μg/ml) |
| S. I. |
| ______________________________________ |
| 21 0.15 36 240 |
| 22 0.021 22 1048 |
| 70 0.026 9.4 362 |
| 71 0.002 4.7 2350 |
| 87 0.003 23 7667 |
| 91 0.063 9.1 144 |
| 93 1.1 65 59 |
| 99 0.008 22 2750 |
| 127 1.5 31 21 |
| 128 0.19 9.2 48 |
| 130 0.014 14 1000 |
| 131 0.29 5.4 19 |
| 138 1.1 9.9 9 |
| 145 0.07 2.7 39 |
| 146 0.3 1.9 6 |
| 149 1.7 8.6 5 |
| 155 0.37 >100 >270 |
| 156 1.8 43 24 |
| 157 0.36 46 128 |
| 159 2.2 11 5 |
| 160 0.32 4.8 15 |
| 161 0.8 8.3 10 |
| 195 1.5 37 25 |
| ______________________________________ |
| TABLE 28 |
| ______________________________________ |
| Compound EC50 CC50 |
| No. (μg/ml) (μg/ml) |
| S. I. |
| ______________________________________ |
| 202 2.5 18 7 |
| 218 0.38 64 168 |
| 219 0.018 46 2556 |
| 220 3.5 63 18 |
| 222 1.4 >100 >71 |
| 223 2.6 >100 >38 |
| 224 0.13 50 385 |
| ______________________________________ |
Industrial applicability:
The arylthiadiazole derivative represented by General Formula [I] or [II] their salts exhibit viricidal effect, and is useful as a viricide.
Watanabe, Hiroyuki, Shigeta, Shiro, Ide, Teruhiko, Baba, Masanori, Fujiwara, Masatoshi, Hanasaki, Yasuaki, Katsuura, Kimio, Yokota, Tomoyuki, Takayama, Hiromitsu, Ijichi, Katsushi, Sakai, Shin-ichiro
| Patent | Priority | Assignee | Title |
| 9301949, | Feb 27 2009 | SIGA TECHNOLOGIES, INC | Thienopyridine derivatives for the treatment and prevention of dengue virus infections |
| Patent | Priority | Assignee | Title |
| JP4182403, | |||
| JP466506, | |||
| WO9320814, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| May 30 1997 | KATSUURA, K | Rational Drug Design Laboratories | DOCUMENT PREVIOUSLY RECORDED AT REEL 8780, FRAME 0973 CONTAINED ERRORS IN PROPERTY NUMBERS 08809936 DOCUMENT RERECORDED TO CORRECT ERRORS ON STATED REEL | 009019 | /0913 | |
| May 30 1997 | WANTANABE, H | Rational Drug Design Laboratories | DOCUMENT PREVIOUSLY RECORDED AT REEL 8780, FRAME 0973 CONTAINED ERRORS IN PROPERTY NUMBERS 08809936 DOCUMENT RERECORDED TO CORRECT ERRORS ON STATED REEL | 009019 | /0913 | |
| May 30 1997 | IDE, T | Rational Drug Design Laboratories | DOCUMENT PREVIOUSLY RECORDED AT REEL 8780, FRAME 0973 CONTAINED ERRORS IN PROPERTY NUMBERS 08809936 DOCUMENT RERECORDED TO CORRECT ERRORS ON STATED REEL | 009019 | /0913 | |
| May 30 1997 | HANASAKI, Y | Rational Drug Design Laboratories | DOCUMENT PREVIOUSLY RECORDED AT REEL 8780, FRAME 0973 CONTAINED ERRORS IN PROPERTY NUMBERS 08809936 DOCUMENT RERECORDED TO CORRECT ERRORS ON STATED REEL | 009019 | /0913 | |
| May 30 1997 | SAKAI, S | Rational Drug Design Laboratories | DOCUMENT PREVIOUSLY RECORDED AT REEL 8780, FRAME 0973 CONTAINED ERRORS IN PROPERTY NUMBERS 08809936 DOCUMENT RERECORDED TO CORRECT ERRORS ON STATED REEL | 009019 | /0913 | |
| May 30 1997 | TAKAYAMA, H | Rational Drug Design Laboratories | DOCUMENT PREVIOUSLY RECORDED AT REEL 8780, FRAME 0973 CONTAINED ERRORS IN PROPERTY NUMBERS 08809936 DOCUMENT RERECORDED TO CORRECT ERRORS ON STATED REEL | 009019 | /0913 | |
| May 30 1997 | YOKOTA, T | Rational Drug Design Laboratories | DOCUMENT PREVIOUSLY RECORDED AT REEL 8780, FRAME 0973 CONTAINED ERRORS IN PROPERTY NUMBERS 08809936 DOCUMENT RERECORDED TO CORRECT ERRORS ON STATED REEL | 009019 | /0913 | |
| May 30 1997 | FUJIWARA, M | Rational Drug Design Laboratories | DOCUMENT PREVIOUSLY RECORDED AT REEL 8780, FRAME 0973 CONTAINED ERRORS IN PROPERTY NUMBERS 08809936 DOCUMENT RERECORDED TO CORRECT ERRORS ON STATED REEL | 009019 | /0913 | |
| May 30 1997 | BABA, M | Rational Drug Design Laboratories | DOCUMENT PREVIOUSLY RECORDED AT REEL 8780, FRAME 0973 CONTAINED ERRORS IN PROPERTY NUMBERS 08809936 DOCUMENT RERECORDED TO CORRECT ERRORS ON STATED REEL | 009019 | /0913 | |
| May 30 1997 | SHIGETA, S | Rational Drug Design Laboratories | DOCUMENT PREVIOUSLY RECORDED AT REEL 8780, FRAME 0973 CONTAINED ERRORS IN PROPERTY NUMBERS 08809936 DOCUMENT RERECORDED TO CORRECT ERRORS ON STATED REEL | 009019 | /0913 | |
| May 30 1997 | IJICHI, K | Rational Drug Design Laboratories | DOCUMENT PREVIOUSLY RECORDED AT REEL 8780, FRAME 0973 CONTAINED ERRORS IN PROPERTY NUMBERS 08809936 DOCUMENT RERECORDED TO CORRECT ERRORS ON STATED REEL | 009019 | /0913 | |
| Jun 09 1997 | Rational Drug Design Laboratories | (assignment on the face of the patent) | / |
| Date | Maintenance Fee Events |
| Feb 14 2003 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
| Mar 28 2007 | REM: Maintenance Fee Reminder Mailed. |
| Sep 07 2007 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| Sep 07 2002 | 4 years fee payment window open |
| Mar 07 2003 | 6 months grace period start (w surcharge) |
| Sep 07 2003 | patent expiry (for year 4) |
| Sep 07 2005 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Sep 07 2006 | 8 years fee payment window open |
| Mar 07 2007 | 6 months grace period start (w surcharge) |
| Sep 07 2007 | patent expiry (for year 8) |
| Sep 07 2009 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Sep 07 2010 | 12 years fee payment window open |
| Mar 07 2011 | 6 months grace period start (w surcharge) |
| Sep 07 2011 | patent expiry (for year 12) |
| Sep 07 2013 | 2 years to revive unintentionally abandoned end. (for year 12) |